2-aminocarbonyl-9h-purine derivatives

专利摘要:
The present invention provides a compound of formula (I), and pharmaceutically acceptable salts and solvent compounds thereof; Their production method; Intermediates used in their preparation; Compositions comprising such compounds; And the use of these compounds: Formula I Where R 1 , R 2 , R 3 , R 4 , R 5 , R 15 , X and Y are each as defined above.
公开号:KR20030032962A
申请号:KR1020027016606
申请日:2001-06-05
公开日:2003-04-26
发明作者:만텔시몬존；스티븐슨피터토마스
申请人:화이자 인코포레이티드；
IPC主号:

专利说明:

2-aminocarbonyl-9H-purine derivative {2-AMINOCARBONYL-9H-PURINE DERIVATIVES}
[2] The derivatives are selective and functional agents of human adenosine A2a receptors and can be used as anti-inflammatory agents, in particular in the treatment of airway diseases.
[3] Adenosine is a ubiquitous molecule that plays a central role in mammalian metabolism. Independently, adenosine acts on numerous surface receptors to produce a variety of responses. It is known that there are four or more subtypes (A1, A2a, A2b and A3) as types of adenosine receptors. Stimulation of adenosine A2 receptors on the surface of human neutrophils has been reported to strongly inhibit a range of neutrophil action. Activated neutrophils and other inflammatory intermediaries reactive oxygen flow (for example, superoxide anion radicals (O ₂ ^{- and))} from the material (for example, human neutrophil elastase (HNE)) and the granular product was ejected lung tissue Can damage it. In addition, active neutrophils newly synthesize and release arachidonate products such as leukotriene B ₄ (LTB ₄ ). LTB ₄ is a potent chemo-attractant that attracts additional neutrophils to the site of inflammation, while released O ₂ ^- and HNE have a deleterious effect on the extracellular matrix of the lung. An A2 receptor subtype that mediates many of these reactions (release of O ₂ ^- and LTB ₄ / HNE and cell attachment) was identified as A2a. A2 subtypes (A2a or A2b) that mediate other effects have not yet been identified.
[4] Animal models and human tissue studies have shown that interactions with other subtypes have a detrimental effect on the lung, resulting in treatments where the agent selective for the A2a receptor is greater than the use of non-selective adenosine receptor agonists. It is believed to provide an advantage. For example, inhalation of adenosine causes bronchial contractions in asthma patients, but not in non-asthmatic patients. This response is at least in part due to the activation of the A1 receptor subtype. In addition, activating the A1 receptor promotes chemotaxis and adhesion of neutrophils to endothelial cells, thereby promoting lung damage. In addition, many patients with respiratory disease will be prescribed a β ₂ -agonist together, resulting in a negative interaction between isoprenin and adenosine receptors negatively bound to adenylate cyclase. Turned out. Selectivity to the A2b receptor is also advantageous because activating the adenosine A2b receptor promotes degranulation in human mast cells.
[1] The present invention relates to purine derivatives. More specifically, the present invention relates to 2-aminocarbonyl-9H-purine derivatives, methods for preparing these derivatives, intermediates used in the preparation of these derivatives, compositions comprising these derivatives and the use of these derivatives.
[5] Surprisingly, the inventors have found that the purine derivatives of the present invention inhibit the action of neutrophils and are selective agents of the adenosine A2a receptor. In addition, the derivative may have agonist activity at the adenosine A3 receptor. Compounds of the invention are adenosine A2a It can be used to treat any disease associated with receptor agonists. Such compounds can be used to treat diseases related to tissue damage induced by leukocytes (eg, neutrophils, eosinophils, basophils, lymphocytes and macrophages). The compound is useful as an anti-inflammatory agent in the treatment of airway diseases such as adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchiectasis, chronic sinusitis and rhinitis. In addition, the compounds of the present invention are septic shock, male impotence, male factor infertility, female factor infertility, hypertension, stroke, epilepsy, cerebral ischemia, peripheral vascular disease, post-ischemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, Psoriasis, dermatitis, allergic dermatitis, eczema, ulcerative colitis, Crohn's disease, inflammatory bowel disease, Helicobacter pylori (Helicobacter pylori) Can be used to treat gastritis, non-Helicobacter pilori gastritis, gastrointestinal damage or psychotic disorders caused by nonsteroidal anti-inflammatory drugs, or to heal wounds.
[6] Thus, in a first aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvent compound thereof:
[7]
[8] Where
[9] R ¹ is H, C ₁ -C ₆ alkyl or fluorenyl, wherein C ₁ -C ₆ alkyl is phenyl, optionally substituted with C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy, halo or cyano And it is unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of naphthyl;
[10] (A) R ² is H or C ₁ -C ₆ alkyl; R ¹⁵ is H or C ₁ -C ₆ alkyl; X is (i) unbranched C ₂ -C ₃ alkylene optionally substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl or (ii) the formula-(CH ₂ ) _n -W- ( CH ₂ ) _p -is a group; W is C ₅ -C ₇ cycloalkylene optionally substituted with C ₁ -C ₆ alkyl; n is 0 or 1; p is 0 or 1;
[11] (B) R ¹⁵ is H or C ₁ -C ₆ alkyl; R ² and X together with the nitrogen atom to which they are attached, azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, unsubstituted or substituted with C ₁ -C ₆ alkyl, respectively, Forms piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; or
[12] (C) R ² is H or C ₁ -C ₆ alkyl; R ¹⁵ and X together with the nitrogen atom to which they are attached, azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, unsubstituted or substituted with C ₁ -C ₆ alkyl, respectively, Forms piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl;
[13] R ³ and R ⁴ together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each on a ring nitrogen or carbon atom Unsubstituted or substituted with -NR ⁶ R ⁷ on a ring carbon atom which is unsubstituted or substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl and which is not adjacent to the ring nitrogen atom; or
[14] R ³ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl; R ⁴ is (a) azetidin-3-yl, pyrrolidin-3- unsubstituted or substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl or het, respectively. 1, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, (b)-(C ₂ -C ₆ alkylene)- R ⁸ , (c)-(C ₁ -C ₆ alkylene) -R ¹³ or (d) C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl;
[15] R ⁵ is CH ₂ OH or CONR ¹⁴ R ¹⁴ ;
[16] R ⁶ and R ⁷ are independently of each other H or C ₁ -C ₆ alkyl; Or together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl or piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl;
[17] R ⁸ is (i) C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₁ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring carbon atom Ring nitrogen atoms, each substituted or unsubstituted with (C ₁ -C ₆ ) -alkyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ⁹ or C ₂ -C ₅ alkanoyl and a fluoro-on ring carbon atoms that are not adjacent - (C ₁ -C ₆₎ - alkoxy, halo, -OR ^{9, _{cyano, -S (O) m R 10}} , -NR 9 R 9, -SO 2 NR 9 Azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4, unsubstituted or substituted with R ⁹ , -NR ⁹ COR ¹⁰ or -NR ⁹ SO ₂ R ¹⁰ . -Yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, wherein said piperazin-1-yl and homopiperazin- 1-yl is C ₁ -C ₆ alkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₂ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring nitrogen atom which is not bound to a C ₂ -C ₆ alkylene group (C ₂ -C ₆ ) -alkyl, flu Oro - (C ₁ -C ₆₎ - alkyl, C ₂ -C ₅ alkanoyl, -COOR ^10, C ₃ -C _{8 ^{cycloalkyl, -SO 2 R 10, -SO 2}} NR 9 R 9 or -CONR ⁹ R Substituted or unsubstituted with ⁹ ; Or (ii) NR ¹¹ R ¹² ;
[18] R ⁹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
[19] R ¹⁰ is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
[20] R ¹¹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl;
[21] R ¹² is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ¹⁰ , C _2- C ₅ alkanoyl or —SO ₂ NR ⁹ R ⁹ ;
[22] R ¹³ is (a) C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy,-(C ₁ -C ₃ alkylene)-(C ₁ -C ₆ alkoxy), halo, cyano,-(C _1- C ₃ alkylene) -CN, -CO ₂ H,-(C ₁ -C ₃ alkylene) -CO ₂ H, -CO ₂ (C ₁ -C ₆ alkyl),-(C ₁ -C ₃ alkylene) -CO ₂ (C ₁ -C ₆ alkyl),-(C ₁ -C ₃ alkylene) -NR ¹⁴ R ¹⁴ , -CONR ¹⁴ R ¹⁴ or-(C ₁ -C ₃ alkylene) -CONR ¹⁴ R ¹⁴ Phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each substituted or unsubstituted; Or (b) azetidin-2-yl, azetidin-3-yl, pyrrolidin-, each optionally substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl or het. 2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-2-yl, homopiperidin- 3-yl or homopiperidin-4-yl;
[23] R ¹⁴ is H, or C ₁ -C ₆ alkyl optionally substituted with cyclopropyl;
[24] m is 0, 1 or 2;
[25] Y is CO, CS, SO ₂ or C = N (CN);
[26] “Het” as used in the definitions of R ⁴ and R ¹³ is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₆ alkoxy, C ₃ -C ₈ cycloalkoxy, hydroxy, oxo or halo Or C-bonded 4 to 6 membered ring heterocycle having 1 to 4 ring nitrogen heteroatoms, substituted or unsubstituted with 1 or 2 nitrogen ring heteroatoms, and 1 oxygen or 1 sulfur ring heteroatom. to be.
[27] In a second aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvent compound thereof:
[28] Formula I
[29]
[30] Where
[31] R ¹ is H, C ₁ -C ₆ alkyl or fluorenyl, wherein C ₁ -C ₆ alkyl is phenyl, optionally substituted with C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy, halo or cyano And it is unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of naphthyl;
[32] R ² is H or C ₁ -C ₆ alkyl;
[33] R ³ and R ⁴ together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each on a ring nitrogen or carbon atom Unsubstituted or substituted with -NR ⁶ R ⁷ on a ring carbon atom which is unsubstituted or substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl and which is not adjacent to the ring nitrogen atom; or
[34] R ³ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl; R ⁴ is (a) azetidin-3-yl, pyrrolidin-3-yl, py, unsubstituted or substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl or het, respectively; Ferridin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, (b)-(C ₂ -C ₆ alkylene) -R ⁸ or (c)-(C ₁ -C ₆ alkylene) -R ¹³ ;
[35] R ⁵ is CH ₂ OH or CONR ¹⁴ R ¹⁴ ;
[36] R ⁶ and R ⁷ are independently of each other H or C ₁ -C ₆ alkyl; Or together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl or piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl;
[37] R ⁸ is (i) C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₁ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring carbon atom Ring nitrogen atoms, each substituted or unsubstituted with (C ₁ -C ₆ ) -alkyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ⁹ or C ₂ -C ₅ alkanoyl and a fluoro-on ring carbon atoms that are not adjacent - (C ₁ -C ₆₎ - alkoxy, halo, -OR ^{9, _{cyano, -S (O) m R 10}} , -NR 9 R 9, -SO 2 NR 9 Azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4, unsubstituted or substituted with R ⁹ , -NR ⁹ COR ¹⁰ or -NR ⁹ SO ₂ R ¹⁰ . -Yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, wherein said piperazin-1-yl and homopiperazin- 1-yl is C ₁ -C ₆ alkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₂ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring nitrogen atom which is not bound to a C ₂ -C ₆ alkylene group (C ₂ -C ₆ ) -alkyl, flu Oro - (C ₁ -C ₆₎ - alkyl, C ₂ -C ₅ alkanoyl, -COOR ^10, C ₃ -C _{8 ^{cycloalkyl, -SO 2 R 10, -SO 2}} NR 9 R 9 or -CONR ⁹ R Substituted or unsubstituted with ⁹ ; Or (ii) NR ¹¹ R ¹² ;
[38] R ⁹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
[39] R ¹⁰ is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
[40] R ¹¹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl;
[41] R ¹² is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ¹⁰ , C _2- C ₅ alkanoyl or —SO ₂ NR ⁹ R ⁹ ;
[42] R ¹³ is phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, optionally substituted with C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy, halo or cyano;
[43] R ¹⁴ is H, or C ₁ -C ₆ alkyl optionally substituted with cyclopropyl;
[44] R ¹⁵ is H or C ₁ -C ₆ alkyl;
[45] m is 0, 1 or 2;
[46] X is unbranched C ₂ -C ₃ alkylene optionally substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl;
[47] Y is CO, CS, SO ₂ or C = N (CN);
[48] "Het" as used in the definition of R ⁴ is substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₆ alkoxy, C ₃ -C ₈ cycloalkoxy, hydroxy, oxo or halo or Unsubstituted 1 to 4 ring nitrogen heteroatoms, or C-bonded 4 to 6 membered ring heterocycles having 1 or 2 nitrogen ring heteroatoms and 1 oxygen or 1 sulfur ring heteroatom.
[49] In the above definition, haloran means fluoro, chloro, bromo or iodo, and alkyl, alkylene, alkanoyl and alkoxy groups containing the required number of carbon atoms, except as indicated, are unbranched or branched. Can be. Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl. Examples of alkoxy include methoxy, ethoxy, n-propoxy, I-propoxy, n-butoxy, i-butoxy, s-butoxy and t-butoxy. Examples of alkanoyls include acetyl and propanoyl. Examples of alkylene include methylene, 1,1-ethylene, 1,2-ethylene, 1,3-propylene and 1,2-propylene. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl (also examples of corresponding cycloalkoxy also apply). Examples of cycloalkylenes include cyclopentylene, cyclohexylene and cycloheptylene. "Het" may be aromatic, partially saturated or fully saturated, and "C-bonded" means that the group is linked to an adjacent group by a ring carbon atom. Examples of “hets” include pyrrolyl, imidazolyl, triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxdiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl do.
[50] Pharmaceutically acceptable salts of compounds of formula I include acid addition salts and base addition salts thereof.
[51] Suitable acid addition salts are formed from acids which form non-toxic salts, for example hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, nitrate, phosphate, phosphate, acetate, maleate, mal Acid salts, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharide, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate, adipate and Xinapoate (1-hydroxy-2-naphthoate) salts.
[52] Suitable base addition salts are formed from bases which form non-toxic salts, for example sodium salts, potassium salts, aluminum salts, calcium salts, magnesium salts, zinc salts and diethanolamine salts.
[53] Suitable salts include Berge et al., J. Pharm. Sci. , 66 , 1-19, 1977.
[54] Pharmaceutically acceptable solvates of compounds of formula I include their hydrates.
[55] Also included within the scope of this invention are polymorphic and radioisotope derivatives of the compounds of formula (I) and salts thereof.
[56] Compounds of formula (I) may exist in two or more stereoisomeric forms because they may contain one or more additional asymmetric carbon atoms. The present invention includes the respective stereoisomers of the compounds of formula (I), and optionally their respective tautomer forms and mixtures thereof.
[57] Diastereomers can be separated by conventional methods, for example, stereoisomeric mixtures of compounds of formula (I), or suitable salts or derivatives thereof, by fractional crystallization, chromatography, or high performance liquid chromatography (HPLC). In addition, enantiomers of the compounds of formula (I) are prepared from the corresponding optically pure intermediates or prepared by, for example, separating the corresponding racemates by HPLC using a suitable chiral support, or optionally The semibodies can be prepared by fractional determination of partial isomeric salts formed by reacting a suitable optically active acid or base.
[58] Preferably, R ¹ is C ₁ -C ₆ is optionally substituted or substituted with non-substituted with one or two phenyl substituents C ₁ -C ₆ alkyl or halo.
[59] Preferably, R ¹ is C ₁ -C ₆ alkyl optionally substituted with one or two phenyl substituents optionally substituted with methyl or chloro.
[60] Preferably, R ¹ is C ₁ -C ₆ alkyl, optionally substituted with one or two phenyl substituents.
[61] Preferably, R ¹ is C ₁ -C ₆ alkyl substituted with one or two phenyl substituents optionally substituted with methyl or chloro.
[62] Preferably, R ¹ is C ₁ -C ₆ alkyl substituted with one or two phenyl substituents.
[63] Preferably, R ¹ is C ₁ -C ₆ alkyl substituted with two phenyl substituents optionally substituted with methyl or chloro.
[64] Preferably, R ¹ is C ₁ -C ₆ alkyl substituted with two phenyl substituents each independently selected from the group consisting of phenyl, 3-methylphenyl and 3-chlorophenyl.
[65] Preferably, R ¹ is C ₁ -C ₆ alkyl substituted with two phenyl substituents.
[66] Preferably, R ¹ is diphenylethyl, bis (3-methylphenyl) ethyl or bis (3-chlorophenyl) ethyl.
[67] Preferably, R ¹ is diphenylethyl.
[68] Preferably, R ¹ is 2,2-diphenylethyl, 2,2-bis (3-methylphenyl) ethyl or 2,2-bis (3-chlorophenyl) ethyl.
[69] Preferably, R ¹ is 2,2-diphenylethyl.
[70] Preferably, R ² is H.
[71] Preferably, R ¹⁵ is H.
[72] Preferably, X is 1,2-ethylene or 1,3-propylene.
[73] Preferably, X is 1,2-ethylene.
[74] Preferably, R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or a group of the formula-(CH ₂ ) _n -W- (CH ₂ ) _p- , W is C ₅ -C ₇ cycloalkylene, n is 0 or 1 and p is 0 or 1.
[75] Preferably, R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or a group of the formula-(CH ₂ ) _n -W- (CH ₂ ) _p- , W is C ₅ -C ₇ cycloalkylene, n is 0 , p is 0.
[76] Preferably, R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or cyclohexylene.
[77] Preferably, R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or 1,4-cyclohexylene.
[78] Preferably, R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or trans-1,4-cyclohexylene.
[79] Preferably, R ² is H; R ¹⁵ is H; X is 1,2-ethylene.
[80] Preferably, R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl, or 3- or 4-piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl.
[81] Preferably, R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl or 4-piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl.
[82] Preferably, R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl, or 3- or 4-piperidinyl.
[83] Preferably, R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl or 4-piperidinyl.
[84] Preferably, R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form (3R) -pyrrolidinyl or 4-piperidinyl.
[85] Preferably, R ² is H; R ¹⁵ and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl, or 3- or 4-piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl.
[86] Preferably, R ² is H; R ¹⁵ and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl or 4-piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl.
[87] Preferably, R ² is H; R ¹⁵ and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl, or 3- or 4-piperidinyl.
[88] Preferably, R ² is H; R ¹⁵ and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl or 4-piperidinyl.
[89] Preferably, R ² is H; R ¹⁵ and X together with the nitrogen atom to which they are attached form (3R) -pyrrolidinyl, (3S) -pyrrolidinyl or 4-piperidinyl.
[90] Preferably, R ³ is H.
[91] Preferably, R ⁴ is piperidin-3-yl or piperidin-4-yl, optionally substituted with benzyl or het, as defined above.
[92] Preferably, R ⁴ is piperidin-3-yl or piperidin-4-yl, optionally substituted with benzyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, respectively, Wherein the pyridin-2-yl, pyridin-3-yl and pyridin-4-yl are each C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₆ alkoxy, C ₃ -C ₈ cycloalkoxy, Unsubstituted or substituted with hydroxy, oxo or halo.
[93] Preferably, R ⁴ is piperidin-3-yl or piperidin-4-yl, each substituted with benzyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, respectively.
[94] Preferably, R ⁴ is piperidin-3-yl or piperidin-4-yl, each substituted with benzyl.
[95] Preferably, R ⁴ is piperidin-3-yl or piperidin-4-yl, each substituted with pyridin-2-yl.
[96] Preferably, R ⁴ is piperidin-4-yl substituted with pyridin-2-yl.
[97] Preferably, R ⁴ is 1-benzylpiperidin-4-yl.
[98] Preferably, R ⁴ is 1- (pyridin-2-yl) piperidin-4-yl.
[99] Preferably, R ⁴ is-(C ₂ -C ₆ alkylene) -R ⁸ .
[100] Preferably, R ⁴ is -CH ₂ CH ₂ R ⁸ .
[101] Preferably, R ⁴ is-(C ₁ -C ₆ alkylene) -R ¹³ .
[102] Preferably, R ⁴ is —CH ₂ R ¹³ or —CH ₂ CH ₂ R ¹³ .
[103] Preferably, R ⁴ is C ₃ -C ₈ cycloalkyl.
[104] Preferably, R ⁴ is cyclohexyl.
[105] Preferably, R ⁵ is -CH ₂ OH or -CONH (C ₁ -C ₆ alkyl).
[106] Preferably, R ⁵ is -CH ₂ OH or -CONHCH ₂ CH ₃ .
[107] Preferably, R ⁵ is -CONHCH ₂ CH ₃ .
[108] Preferably, R ⁸ is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, each substituted or unsubstituted with C ₁ -C ₆ alkyl on the ring carbon atom , Morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, wherein the piperazin-1-yl And homopiperazin-1-yl is unsubstituted or substituted with C ₁ -C ₆ alkyl on a ring nitrogen atom which is not bonded to a C ₂ -C ₆ alkylene group; Or (ii) NR ¹¹ R ¹² .
[109] Preferably, R ⁸ is piperidin-1-yl or tetrahydroisoquinolin-1-yl, each optionally substituted with C ₁ -C ₆ alkyl on the ring carbon atom.
[110] Preferably, R ⁸ is piperidin-1-yl, each substituted or unsubstituted with isopropyl on the ring carbon atom.
[111] Preferably, R ⁸ is piperidin-1-yl, 4-isopropylpiperidin-1-yl or tetrahydroisoquinolin-1-yl.
[112] Preferably, R ⁸ is NR ¹¹ R ¹² and NR ¹¹ R ¹² is N (C ₁ -C ₆ alkyl) ₂ , N (C ₁ -C ₆ alkyl) (C ₃ -C ₈ cycloalkyl) or N ( C ₁ -C ₆ alkyl) (benzyl).
[113] Preferably, R ⁸ is NR ¹¹ R ¹² , and NR ¹¹ R ¹² is N, N-diisopropylamino, N, N-di-n-butylamino, N-cyclopentyl-N-isopropylamino, N -Cyclohexyl-N-isopropylamino or N-benzyl-N-isopropylamino.
[114] Preferably, R ¹¹ is H or C ₁ -C ₆ alkyl.
[115] Preferably, R ¹¹ is C ₁ -C ₆ alkyl.
[116] Preferably, R ¹¹ is isopropyl or n-butyl.
[117] Preferably, R ¹² is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl.
[118] Preferably, R ¹² is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl.
[119] Preferably, R ¹² is isopropyl, cyclopentyl, cyclohexyl or benzyl.
[120] Preferably, R ¹³ is phenyl unsubstituted or substituted with — (C ₁ -C ₃ alkylene) -NR ¹⁴ R ¹⁴ or —CO ₂ H; Or piperidin-2-yl, piperidin-3-yl or piperidin-4-yl, each substituted or unsubstituted with benzyl.
[121] Preferably, R ¹³ is phenyl unsubstituted or substituted with —CH ₂ N (CH ₂ CH ₃ ) ₂ or —CO ₂ H; Or piperidin-4-yl substituted with benzyl.
[122] Preferably, R ¹³ is phenyl, 4- (N, N-diethylamino) methylphenyl, 4-carboxyphenyl or 1-benzylpiperidin-4-yl.
[123] Preferably, R ¹⁴ is H or C ₁ -C ₆ alkyl.
[124] Preferably, R ¹⁴ is H or ethyl.
[125] Preferably, Y is CO.
[126] Preferably,
[127]
[128]
[129]
[130]
[131] Where
[132] "Et" means ethyl;
[133] "iPr" means isopropyl;
[134] "nBu" means n-butyl;
[135] "Ph" means phenyl.
[136] Particularly preferred embodiments of the compounds of formula (I) are the compounds of the example moieties, in particular the compounds of examples 8 and 34, and pharmaceutically acceptable salts and solvent compounds thereof.
[137] Compounds of formula (I) are conventional unless R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ¹⁵ , X and Y are defined as the following exemplary methods as defined above for compounds of formula (I) It can be prepared using the method.
[138] 1. Compounds of formula I, wherein Y is CO, can be prepared by reacting a compound of formula II with a compound of formula III:
[139]
[140] R ³ R ⁴ NCOZ ¹
[141] In the above formulas,
[142] Z ¹ is a suitable leaving group such as chloro or 1H-imidazol-1-yl.
[143] In a typical method, the compound is reacted in a suitable solvent such as toluene, isopropanol, dichloromethane, or any combination thereof, optionally with heating, for example at reflux temperature of the solvent.
[144] Compounds of formula III can be prepared by conventional methods.
[145] Compounds of formula II can be prepared as shown in Schemes 1a and 1b:
[146]
[147]
[148] In the above formulas,
[149] R ¹⁶ is C ₁ -C ₄ alkyl;
[150] R ¹⁷ is a suitable protecting group such as tetrahydro-2H-pyran-2-yl;
[151] R ¹⁸ is a suitable ester forming group such as C ₁ -C ₆ alkyl or benzyl, preferably C ₁ -C ₄ alkyl;
[152] R ¹⁹ and R ²⁰ are each suitable protecting groups such as acetyl or benzoyl, or both are suitable protecting groups such as C ₁ -C ₆ alkylene which may be substituted or unsubstituted with phenyl, for example 1,1-dimethylmethylene or phenylmethylene. .
[153] In a typical method where R ¹⁷ is tetrahydro-2H-pyran-2-yl, such as p-toluenesulfonic acid (PTSA), benzenesulfonic acid, camphorsulfonic acid, hydrochloric acid, sulfuric acid, methanesulfonic acid or p-toluenesulfonate In the presence of a suitable acid catalyst in an appropriate solvent such as ethyl acetate, toluene, dichloromethane, dimethylformamide (DMF), tert-butyl methylether, diisopropylether, tetrahydrofuran (THF) or acetonitrile The chloropurine of formula IV is reacted with 3,4-dihydro-2H-pyran at the reflux temperature of the solvent to N-protect. The reaction is preferably carried out in ethyl acetate in the presence of PTSA while heating. Suitable other protecting groups R ¹⁷ are described in Greene et al., Cited herein.
[154] The prepared compound of formula 5 can be converted to an amine of formula VI by reacting with a compound of formula XVI:
[155] R ¹ NH ₂
[156] The compound is reacted at room temperature to the reflux temperature of the solvent in a suitable solvent such as methanol, ethanol or isopropanol in the presence of a suitable acid acceptor such as triethylamine, 4-methylmorpholine or N-ethyldiisopropylamine. Preferably N-ethyldiisopropylamine and isopropanol are used under reflux conditions.
[157] The amine of formula VI is then reacted with sodium or potassium thioalkoxide at room temperature to reflux of the solvent in a suitable solvent such as dimethylsulfoxide (DMSO), DMF or 1-methyl-2-pyrrolidinone. Preferably sodium or potassium thiomethoxide is used at 100 ° C. under reflux conditions in DMF.
[158] Oxone® (potassium peroxymonosulfate), dimethyl dioxirane at a temperature from room temperature to 50 ° C. in a suitable solvent such as aqueous acetone or dichloromethane in the presence of a suitable base such as sodium bicarbonate Using a suitable oxidizing agent such as m-chloroperbenzoic acid or peracetic acid, the thioether of formula (VII) is oxidized to sulfone of formula (VIII). Preferably, oxone and sodium bicarbonate are used at room temperature in aqueous acetone.
[159] In a suitable solvent such as DMSO, DMF, 1-methyl-2-pyrrolidinone, THF or acetonitrile, the sulfone of formula VIII is reacted with a suitable cyanide such as potassium cyanide, zinc cyanide, sodium cyanide or copper cyanide at room temperature to the reflux temperature of the solvent. It can be converted to the nitrile of formula IX by reacting with a cargo source. Preferred conditions use potassium cyanide at 120 ° C. in DMF.
[160] Alternatively, the tree in a suitable solvent such as DMF, DMSO, 1-methyl-2-pyrrolidinone, THF or acetonitrile using a suitable cyanide source such as potassium cyanide, zinc cyanide, sodium cyanide or copper cyanide. Phenylphosphine, tri-o-tolylphosphine, (R)-or (S)-or racemic-2,2'-bis (diphenylphosphino) -1,1'-binafyl, or 1, Optional presence of a suitable palladium catalyst such as tetrakis (triphenylphosphine) palladium (0) or palladium (II) acetate in admixture with 1'-bis (diphenylphosphino) ferrocene, for example In the presence of triethylamine, 4-methylmorpholine or N-ethyldiisopropylamine, it is possible to convert chloropurine of formula VI to nitrile of formula IX at room temperature to the reflux temperature of the solvent (under selective pressure). . Alternatively, the reaction can be carried out by reacting chloropurine of formula VI with sodium cyanide or potassium cyanide at room temperature to the reflux temperature of the solvent in a suitable solvent such as DMSO, 1-methyl-2-pyrrolidinone or DMF. . Preferably, the reaction is carried out at 80-85 ° C. under elevated pressure of argon in DMF using zinc cyanide, triethylamine and tetrakis (triphenylphosphine) palladium (0).
[161] Deprotection of the nitrile of formula (IX) under conventional conditions can yield the nitrile of formula (X). For example, when R ¹⁷ is tetrahydro-2H-pyran-2-yl, the deprotection may be hydrochloric acid, trifluoroacetic acid, sulfuric acid, trichloroacetic acid, phosphoric acid, p-toluenesulfonic acid, benzenesulfonic acid, methane In a solvent such as C ₁ -C ₄ alkanol which may or may contain water in the presence of a suitable acid such as sulfonic acid or camphorsulfonic acid, it may be carried out at elevated temperatures, preferably at the reflux temperature of the solvent. In work up, the pH can be adjusted to 8-11 with an aqueous base such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate to produce the free base of the compound of formula X. Preferred conditions are using 2M aqueous hydrochloric acid in ethanol at room temperature or trifluoroacetic acid in aqueous isopropanol under reflux conditions, followed by adjusting the pH to 9-10.5 in working up using aqueous sodium hydroxide solution.
[162] The esters of formula (XII) can be converted by reacting the nitrile of formula (X) with sodium or potassium C ₁ -C ₄ alkoxide in a corresponding C ₁ -C ₄ alkanol solvent at optional elevated temperatures, including acid treatment, during workup. Preferably, the reaction is carried out using sodium methoxide in methanol at reflux with acid treatment with aqueous hydrochloric acid during workup.
[163] Alternatively, the compounds of formula VI are carbonylated with compounds of formula R ¹⁸ OH at elevated temperatures, optionally in the presence of a suitable base, for example tertiary amine base, with a suitable palladium catalyst under selective pressure using carbon monoxide. Esters of XII can be prepared to yield compounds of formula VIA:
[164]
[165] Typically, suitable ligands (eg, 1,1'-bis (diphenylphosphino) ferrocene, triphenyl phosphine, tri-o-tolylphosphine or BINAP ((R)-, (S)-or racese) A catalytic amount of palladium acetate (II), a suitable alcohol of formula R ¹⁸ OH, with a mild-2,2'-bis (diphenylphosphino) -1,1'-binafyl), e.g. methanol, ethanol , 1-propanol, isopropanol or 1-butanol (also used as solvent) and bases (e.g. triethylamine, Hunigs base (ethyldiisopropylamine), 4-methylmorpholine, sodium carbonate, Sodium bicarbonate, potassium carbonate or cesium carbonate) is used in a sealed vessel at 20-200 ° C. under carbon monoxide, optionally under a pressure of 1-3000 kPa. Deprotecting the compound of formula (VIA) can be obtained using appropriate deprotection conditions, such as those described in connection with converting the compound of formula (IX) to the compound of formula (X).
[166] Esters of formula (XII) may be coupled with compounds of formula (XI):
[167]
[168] Where
[169] Z ² is a suitable leaving group such as acetoxy, benzoyloxy, methoxy or halo, for example chloro;
[170] R ¹⁹ and R ²⁰ are suitable acid or Lewis acids, for example trimethylsilyl trifluoromethanesulfonate, preferably with an excess of these and suitable protecting groups as defined above.
[171] The reaction can be carried out using the compound of formula XI in the form of 2R- or 2S-diastereomers, or epimer mixtures thereof. The reaction is optionally carried out in the presence of a tertiary amine base, for example N-methylmorpholine, preferably with the compound of formula XII in a suitable silylating agent, for example trimethylsilyl trifluoromethanesulfonate, N By pre-reaction with, O-bis (trimethylsilyl) acetamide, trimethylsilyl chloride or hexamethyldisilazane followed by the addition of a compound of formula (XI) typically a suitable solvent such as 1,2-dimethoxyethane, dichloro Methane, acetonitrile, 1,1,1-trichloroethane or toluene, or mixtures thereof. An elevated temperature is used in this reaction. Preferred conditions are first reacting the compound of formula XII with N, O-bis (trimethylsilyl) acetamide in 1,1,1-trichloroethane with heating the reaction solution under reflux, followed by the compound of formula XI in toluene. Reacting with a solution of trimethylsilyl trifluoromethanesulfonate followed by heating above 100 ° C. When using compounds of formula (XI) wherein R ⁵ is CH ₂ OH, the hydroxyl groups may be suitably protected for this reaction (see R ^5A below) and then deprotected in subsequent modifications to produce compounds of formula XIV. Will be self explanatory.
[172] Compounds of formula (XIII) are prepared under the usual conditions, for example methanol, ethanol, under basic conditions using sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate or cesium carbonate when R ¹⁹ and R ²⁰ are each acetyl or benzoyl, respectively. In a solvent such as isopropanol, 1,2-dimethoxyethane, THF, DMF, acetone, 2-butanone or 4-methyl-2-pentanone can be deprotected at a temperature of 0 to 80 ° C. in the selective presence of water. . Alternatively, tertiary amine bases such as triethylamine, diisopropylethylamine or 4-methylmorpholine can be used at temperatures from 0 to 80 ° C. in alcohol solvents such as methanol, ethanol, isopropanol or 1-propanol or Or sodium or potassium C ₁ -C ₄ alkoxides, for example methoxide or ethoxide, can be used in the corresponding C ₁ -C ₄ alkanols, for example methanol or ethanol. In addition, amines (eg ammonia, methylamine, ethylamine or dimethylamine) and suitable solvents (eg methanol, ethanol, isopropanol, THF or dichloromethane) can be used at temperatures of 0-80 ° C. Preferably sodium carbonate is used in methanol at room temperature.
[173] Under selective pressure in an optional inert solvent such as 1,2-dimethoxyethane or 2-methoxyethyl ether at selective elevated temperatures, the ester of formula XIV can be converted to the amide of formula II by reacting with a compound of formula XV have:
[174] R ¹⁵ NH-X-NHR ²
[175] Preferably, the reaction is carried out at a temperature of 100 to 120 ° C. in the absence of solvent. Appropriate protecting groups (e.g., trifluoroacetyl) located on selected N atoms of the compound of formula XV can be optionally used in the reaction and deprotected after the protected intermediate has been produced to achieve the desired position selectivity. Will be apparent to those skilled in the art.
[176] Compounds of formula (II) can also be prepared by aminocarbonylation of compounds of formula (XVII) with compounds of formula (XV) in a manner analogous to that described below for converting compounds of formula (XVII) to compounds of formula (I):
[177] Formula XV
[178] R ¹⁵ NH-X-NHR ²
[179] Appropriate protecting groups (e.g., trifluoroacetyl) located on selected N atoms of the compound of formula XV can be optionally used in the reaction and deprotected after the protected intermediate has been produced to achieve the desired position selectivity. Will be apparent to those skilled in the art.
[180] Compounds of formula (XI) or (XV) may be prepared by conventional methods.
[181] 2. A compound of formula (I), wherein Y is CO, may be substituted with a compound of formula (XVII) in the presence of carbon monoxide and a suitable coupling catalyst (also this route may be used for compounds of formula (I) It can be prepared by aminocarbonylation with a compound of formula XVIII:
[182]
[183] R ¹⁵ NH-X-NR ² -Y-NR ³ R ⁴
[184] In the above formulas,
[185] Z ³ is a suitable leaving group such as bromo, iodo, —Sn (C ₁ -C ₁₂ alkyl) ₃ or CF ₃ SO ₂ O—, preferably iodo.
[186] The catalyst is preferably a palladium (II) catalyst, more preferably 1,1'-bis (diphenylphosphino) ferrocene dichloropalladium (II) (optionally as a 1: 1 complex with dichloromethane). Alternatively, palladium acetate (II) may be reacted with 1,1'-bis (diphenylphosphino) ferrocene, triphenylphosphine, tri (o-tolyl) phosphine, or (R)-, (S)-or racese. It can be used in the presence of a suitable ligand such as U.S.-2,2'-bis (diphenylphosphino) -1,1'-binafthyl.
[187] In a typical process, the reaction is a vessel sealed in a suitable solvent such as tetrahydrofuran, methanol or ethanol at elevated pressure, eg about 345 kPa (50 psi) and elevated temperature, eg about 60 ° C., in the presence of carbon monoxide. Is performed in Alternatively, suitable organic bases may be present, such as tertiary amines such as triethylamine, N-ethyldiisopropylamine or 4-methylmorpholine.
[188] Intermediates of formula (XVII) can be prepared as shown in Scheme 2:
[189]
[190] Where
[191] R ^5A is as defined below;
[192] Z ³ is as defined above for the compound of Formula XVII;
[193] "Ac" is acetyl (though it will be apparent that other suitable protecting groups as exemplified herein may be used in this modification).
[194] In a typical process, the compound of formula (XIX) is reacted with an amine of formula (XVI) in the presence of a suitable acid acceptor, for example triethylamine, in an appropriate solvent such as, for example, acetonitrile, optionally at elevated temperature:
[195] Formula XVI
[196] R ¹ NH ₂
[197] The obtained product of formula (XX) is deprotected by hydrolysis to obtain conventional methods, for example suitable inorganic bases (e.g. sodium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate or cesium carbonate) and suitable solvents ( Optionally aqueous conditions, using methanol, ethanol, isopropanol, 1,2-dimethoxyethane, tetrahydrofuran, dimethylformamide, acetone, 2-butanone or 4-methyl-2-pentanone) Under this, compounds of formula (XVII) can be obtained at reflux temperature of the solvent, for example at room temperature. Alternatively, the deprotection may be effected using methanol, ethanol, n-propanol, using a suitable amine base such as triethylamine, diisopropylethylamine, 4-methylmorpholine, ammonia, methylamine, ethylamine or dimethylamine. In a suitable solvent such as isopropanol, tetrahydrofuran or dichloromethane.
[198] Intermediates of formula (XIX) can be prepared by conventional methods.
[199] Intermediates of formula (XVIII) may be prepared by reacting a compound of formula (XV) with a compound of formula (III) under conditions similar to those described above for converting compounds of formulas (II) and (III) to compounds of formula (I):
[200] Formula XV
[201] R ¹⁵ NH-X-NHR ²
[202] Formula III
[203] R ³ R ⁴ NCOZ ¹
[204] Appropriate protecting groups (e.g. trifluoroacetyl) located on selected N atoms of the compound of formula XV can be optionally used in the reaction and deprotected after the protected intermediate has been prepared to achieve the desired positional selectivity. Will be apparent to those skilled in the art.
[205] 3. Compounds of formula I, wherein Y is CO, may be prepared by deprotecting the compound of formula XXI:
[206]
[207] Where
[208] R ^5A is CH ₂ OH, CH ₂ OR ²³ or CONR ¹⁴ R ¹⁴ ;
[209] R ²¹ and R ²² are each suitable protecting groups such as acetyl or benzoyl, or both suitable protecting groups such as C ₁ -C ₆ alkylene which may be substituted or unsubstituted with phenyl, for example 1,1-dimethylmethylene or phenylmethylene ;
[210] R ²³ is a suitable protecting group such as acetyl or benzoyl (also it will be apparent that this route can also be used for compounds of formula I in which Y is not CO).
[211] Conventional deprotection conditions may be used and the protecting groups R removed²¹, R²²And R²³It will depend on the type of. In addition, protector R²¹, R²²And R²³It will be apparent to one skilled in the art that all of together may be removed alone or in any combination to produce a compound of formula (I). For example, R^5ACH₂OR²³If R²²Is first deprotected and then R²³May be removed or conversely deprotected. R²¹, R²²And R²³In a typical method where each of these is acetyl, the deprotection may be effected with a suitable inorganic base (e.g. sodium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate or cesium carbonate) and a suitable solvent (e.g. methanol, ethanol, isopropanol). , 1,2-dimethoxyethane, tetrahydrofuran, dimethylformamide, acetone, 2-butanone or 4-methyl-2-pentanone), optionally under aqueous conditions, from 0 ° C. to the reflux temperature of the solvent For example at room temperature. Alternatively, the deprotection can be effected using methanol, ethanol, n-propanol, In a suitable solvent such as isopropanol, tetrahydrofuran or dichloromethane, or may be carried out at reflux temperature of the solvent from 0 ° C., or sodium or potassium C_One-C₄Corresponding C using alkoxides, for example sodium methoxide or ethoxide_One-C₄Alkanols, for example methanol or ethanol.
[212] In a typical method where R ²¹ and R ²² are both 1,1-dimethylmethylene, the compounds of formula XXI are prepared with hydrochloric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid under the optional presence of a suitable solvent such as ethanol and optional aqueous conditions. It can be deprotected by treatment with a suitable acid or acidic ion exchange resin such as pyridinium p-toluenesulfonate, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, acetic acid, formic acid or mixtures thereof. The reaction can be carried out at an elevated temperature, such as the reflux temperature of the solvent.
[213] In addition, deprotection of a compound of formula (XXI) to produce a compound of formula (I) may be performed in its original state after conversion of the compound of formula (XXII) to a compound of formula (XXI) as described below. Here, R²¹, R²²And R²³If each of these is acetyl, a deprotection method using an inorganic base is preferred, for example a reaction mixture comprising a compound of formula XXI is treated with aqueous sodium hydroxide solution at 5 to 20 ° C. in 1,2-dimethoxyethane.
[214] Compounds of Formula (XXI) may be prepared by coupling a compound of Formula (XXII) with a compound of Formula (XXIII):
[215]
[216]
[217] In the above formulas,
[218] Z ⁴ is a suitable leaving group such as acetoxy, benzoyloxy, methoxy or halo, for example chloro, under conditions similar to those described above with regard to the process for converting a compound of formula XII to a compound of formula XIII.
[219] Compounds of Formula (XXII) can be prepared using conventional methods, as shown in Scheme 3 below. Such methods may be modified from the methods described herein above:
[220]
[221] Where
[222] R ²⁴ is a suitable protecting group such as tetrahydro-2H-pyran-2-yl.
[223] Acids of formula XXVI can be prepared by conventional methods, for example by basic hydrolysis of compounds of formula IX using aqueous sodium hydroxide solution followed by acidification in workup.
[224] Compounds of formula (XXIII) can be prepared by conventional methods.
[225] In addition, compounds of Formula XXI wherein R ^5A is CONR ¹⁴ R ¹⁴ may be prepared as shown in Schemes 4a to 4c:
[226]
[227]
[228]
[229] In a typical method, compounds of formula (XII) are reacted with compounds of formula (XXIII) wherein R ^5A is CH ₂ OR ²³ using conditions similar to those described above for the process of converting a compound of formula (XII) to a compound of formula (XIII).
[230] The compound of formula XXX prepared is prepared under conventional conditions, such as R²¹, R²²And R²³Each of acetyl, sodium carbonate, carbonic acid for up to 24 hours in the presence of a suitable alcoholic solvent, for example ethanol, the selective presence of other solvents, for example 1,2-dimethoxyethane, the selective presence of water and the optional elevated temperature. It may be deprotected under conditions using a suitable base such as potassium, sodium ethoxide, sodium methoxide or potassium tert-butoxide and optionally directly using the crude reaction mixture obtained in the previous step.
[231] The compound of formula XXXI prepared may be protected with a suitable protecting group or suitable protecting groups. R²¹And R²²When both represent 1,1-dimethylmethylene, the protection is in the presence of hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid, sulfuric acid, phosphoric acid or trifluoroacetic acid such as acetone, toluene, dichloromethane or tetrahydrofuran. It may be carried out by reacting with acetone, ketal of acetone or a mixture of both at selective elevated temperatures in the solvent. Preferably, the reaction is carried out using acetone and 2,2-dimethoxypropane in the presence of sulfuric acid.
[232] Alternatively, selective enzymatic hydrolysis, for example using a suitable lipase enzyme, can be used to directly convert a compound of formula XXX to a compound of formula XXXII.
[233] Prepared by a one-step method of reacting with a suitable oxidant in a suitable solvent or by a two-step method of first reacting with a suitable oxidant in a suitable solvent to produce the corresponding aldehyde and subsequently reacting with a suitable oxidant in a suitable solvent. Compounds of formula (XXXII) may be oxidized to carboxylic acids of formula (XXXIII). Typical one-step process conditions include ruthenium trioxide, ruthenium chloride, 2,2,6,6-tetramethylpiperidinyl-1-oxy free radicals or platinum in a suitable solvent such as acetonitrile, dichloromethane, toluene or ethyl acetate. Optional presence of suitable catalysts, such as sodium hypochlorite, sodium bromide or potassium bromide, selective presence of water, quaternary-butylammonium bromide, benzyl triethylammonium chloride or quaternary-butyl ammonium chloride The primary alcohol is converted into chromic acid, sodium peroxate, trioxide in the presence of an optional phase transfer catalyst, in the presence of an inorganic base such as sodium carbonate, sodium bicarbonate, potassium carbonate or sodium hydroxide and in the optional presence of additional additives such as sodium chloride. Chromium, potassium permanganate, sodium chlorite, sodium hypochlorite or oxygen It includes the same oxidant and reacting. The conditions of a suitable two-step method are initially determined in the presence of an additional oxidant such as N-methylmorpholine-N-oxide in a suitable solvent, Swern reagent, tetrapropylammonium perruthenate, pyridinium dichromate, pyridinium After reaction with an oxidizing agent such as chlorochromate, sulfur trioxide-pyridine complex or 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3 (1H) -one, acetonitrile, dichloro Selective presence of a suitable catalyst such as ruthenium trioxide, ruthenium chloride, 2,2,6,6-tetramethylpiperidinyl-1-oxyfree radicals or platinum in a suitable solvent such as methane, toluene or ethyl acetate, sodium hypochlorite Selective presence of additional catalyst, such as sodium bromide or potassium bromide, selective presence of water, quaternary-butylammonium bromide, benzyl triethylammonium chloride or quaternary-part Intermediate aldehydes in the presence of a selective phase transfer catalyst such as ammonium chloride, an optional presence of inorganic bases such as sodium carbonate, sodium bicarbonate, potassium carbonate or sodium hydroxide and additional additives such as sodium chloride, chromic acid, sodium peroxoate And reacting with other suitable oxidants such as chromium trioxide, potassium permanganate, sodium chlorite, sodium hypochlorite or oxygen. Preferred conditions are the reaction of an alcohol of formula XXXII with a catalytic amount of 2,2,6,6-tetramethylpiperidinyl-1-oxy free radical in the presence of water and sodium dihydrogen phosphate in acetonitrile followed by aqueous sodium hypochlorite ( Catalytic amount) and aqueous sodium chlorite are added and reacted at elevated temperature. Alternatively, an alcohol of formula XXXII is prepared with 2,2,6,6-tetramethylpiperidinyl-1-oxy free radicals (catalyst amount) and char in the presence of water, sodium bicarbonate and catalytic amounts of tetrabutylammonium bromide in dichloromethane. React with sodium chlorate.
[234] The carboxylic acid of formula XXXIII prepared using the conventional coupling conditions in which an acid is activated with a suitable activator in the selective presence of a catalyst and then reacted with an excess of an amine of formula HNR ¹⁴ R ^{14 in} a suitable solvent to Can be converted to amides. Typically, the reaction is carried out with N ', N'-carbonyldiimine for 1-20 hours at a temperature of 0-100 ° C. in a solvent such as THF, DMF, ethyl acetate, acetonitrile, toluene, acetone or dichloromethane. Tertiary amino acid acceptor at 0-100 ° C. in the presence of triethylamine, ethyldiisopropylamine or N-methylmorpholine after reaction with an activator such as dozol, thionyl chloride, olsalyl chloride or phosphorus oxychloride By addition of an amine or an acid addition salt thereof in the presence of Alternatively, the acid is reacted with 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride or N, N'-dicyclohexylcarbodiimide followed by 1-hydroxy-7-azabenzo After reaction with triazole or 1-hydroxybenzotriazole hydrate, in the presence of excess 4-methylmorpholine, triethylamine or ethyldiisopropylamine, THF, DMF, ethyl acetate, acetonitrile, toluene, acetone or dichloro React with amines at room temperature in methane. This reaction is also carried out by the reaction of the acid with benzotriazol-1-yloxytris (pyrroli) at room temperature in THF, DMF, dichloromethane or ethylacetate in the presence of 4-methylmorpholine, triethylamine or ethyldiisopropylamine. Dino) phosphonium hexafluorophosphate, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate or Mukaiyama reagent (2-chloro-1-methylpyridinium iodide), and reaction with amines Can be carried out. Preferably the reaction is carried out by initially reacting the acid with N ', N'-carbonyldiimidazole in ethyl acetate followed by addition of an amine in THF.
[235] Under conventional ester hydrolysis conditions in which an alkali metal base is used in a suitable solvent at an optional elevated temperature in the presence of water and then reacted with an acid to produce a carboxylic acid, the compound of formula (XXXIV) can be hydrolyzed to produce a carboxylic acid of formula (XXXV). . In a typical reaction, the reaction is carried out from 0 to using lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent such as aqueous ethanol, methanol, isopropanol, butanol, industrial methylated alcohol, tetrahydrofuran, DMF or 1,2-dimethoxyethane. It is carried out at 100 ° C. Preferably, the reaction is carried out at 20-65 ° C. using sodium hydroxide in a mixture of methanol and water.
[236] The acid of formula XXXV prepared is converted to the amide of formula XXI, using conventional coupling conditions in which the acid is activated with a suitable alkylating agent in an optional solvent in the presence of a catalyst and then reacted with an excess of an amine of formula XVIII can do:
[237] Formula XVIII
[238] R ¹⁵ NH-X-NR ² -Y-NR ³ R ⁴
[239] In a typical method, the acid is replaced with N ', N'-carbonyldiimidazole, thionyl chloride, oxalyl chloride or phosphorus oxychloride in a solvent such as THF, DMF, ethyl acetate, acetonitrile, toluene, acetone or dichloromethane. And react at 0-100 占 폚 by adding an amine or an acid addition salt thereof in the optional presence of a tertiary amine such as triethylamine, ethyldiisopropylamine or N-methylmorpholine. . Alternatively, the acid is reacted with 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride or N, N'-dicyclohexylcarbodiimide followed by 1-hydroxy-7-azabenzo After reaction with triazole or 1-hydroxybenzotriazole hydrate, in the presence of excess 4-methylmorpholine, triethylamine or ethyldiisopropylamine, THF, DMF, ethyl acetate, acetonitrile, toluene, acetone or dichloro React with amines at room temperature in methane. This reaction also allows the acid to be converted to benzotriazol-1-yloxytris (pyrroli) at room temperature in THF, DMF, dichloromethane or ethylacetate in the presence of 4-methylmorpholine, triethylamine or ethyldiisopropylamine. Dino) phosphonium hexafluorophosphate, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate or mukaiyama reagent (2-chloro-1-methylpyridinium iodide), and amine Can be. Preferably the reaction is carried out initially by reacting the acid with N ', N'-carbonyldiimidazole in dichloromethane and optionally in the presence of an acid acceptor such as triethylamine in the form of a suitable acid addition salt such as hydrochloride. It is carried out by adding and reacting at room temperature.
[240] In addition, compounds of Formula (XXXIII) can be prepared as shown in Scheme 5:
[241]
[242] Optionally such as sodium hypochlorite in the presence of catalytic amounts of 2,2,6,6-tetramethylpiperidinyl-1-oxy free radicals and bromide ions (given as sodium bromide, potassium bromide or tetraalkylammonium bromide) With an oxidizing agent or in the presence of a platinum catalyst in a suitable solvent such as water, acetonitrile, dichloromethane, toluene or ethyl acetate, or with a phase transfer catalyst such as tetrabutylammonium bromide, tetrabutylammonium chloride or benzyltriethylammonium chloride Together, oxygen in the mixture of organic solvent and water can be used to selectively oxidize the triol of formula XXXI to produce the diol of formula XXXVII.
[243] The diols of formula XXXVII can be protected using suitable protecting groups or suitable protecting groups. If the protecting group is 1,1-dimethylmethylene, the protection may be achieved by reacting with acetone or induction of acetone in the presence of an acidic reagent. In a typical reaction, diols may be converted to acetone or acetone in a solvent such as acetone, toluene, dichloromethane or tetrahydrofuran in the presence of acids such as hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid, sulfuric acid, phosphoric acid or trifluoroacetic acid. The ketal, for example 2,2-dimethoxypropane, or a mixture of both, is reacted at an optional elevated temperature.
[244] In addition, compounds of Formula XXI wherein R ^5A is CONR ¹⁴ R ¹⁴ may be prepared as shown in Schemes 6a and 6b:
[245]
[246]
[247] In a typical method, compounds of formula XXI wherein R ^5A is CH ₂ OR ²³ and R ²¹ , R ²² and R ²³ are suitable protecting groups such as acetyl are selected from other solvents such as 1,2-dimethoxyethane in a suitable alcohol solvent. In the presence and in the selective presence of water, it is deprotected under conventional conditions which react with a base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium ethoxide, sodium methoxide or potassium tert-butoxide.
[248] The compounds of formula XXXVIII prepared can be optionally protected under conventional conditions. Where both R ²¹ and R ²² represent 1,1-dimethylmethylene, the protection is acetone, toluene, in the presence of an acid such as hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid, sulfuric acid, phosphoric acid or trifluoroacetic acid, It can be achieved by reacting triol in a solvent such as dichloromethane or tetrahydrofuran at selective elevated temperatures with a mixture of acetone or a ketal of acetone, for example 2,2-dimethoxypropane, or both.
[249] Alternatively, the compound of formula (XXI) can be converted directly to the compound of formula (XXXIX) by selective enzymatic hydrolysis, for example by a suitable lipase enzyme.
[250] Alcohols of formula (XXXIX) can be oxidized to acids of formula (XXXX) using conditions similar to those described above for methods of converting compounds of formula (XXXII) to compounds of formula (XXXIII).
[251] Acids of formula (XXXX) can be oxidized to amides of formula (XXI) using conditions similar to those described above for methods of converting compounds of formula (XXXIII) to compounds of formula (XXXIV).
[252] 4. A compound of formula I wherein Y is CS may be prepared by reacting a compound of formula Z ⁵ CS.Z ^{6 with} a compound of formula II and then reacting the intermediate of formula XXIVA obtained with an amine of formula R ³ R ⁴ NH Can:
[253]
[254] Where
[255] Z ⁵ and Z ⁶ are the same or different suitable leaving groups, respectively, and may typically be selected from the group consisting of -S (C ₁ -C ₆ alkyl) and 1H-imidazol-1-yl.
[256] 5. A compound of formula (I) wherein Y is SO ₂ may be prepared by reacting a compound of formula (XXVII) with a compound of formula (II) in the selective presence of an acid acceptor. Compounds of formula (XXVII) can be prepared by conventional methods of activation from compounds of formula (XXVIII) using, for example, PCl _{5 wherein} Z ⁷ is Cl. Compounds of formula XXVIII may be prepared by reacting chlorosulfonic acid with an amine of formula R ³ R ⁴ NH:
[257] R ³ R ⁴ NSO ₂ Z ⁷
[258] R ³ R ⁴ NSO ₃ H
[259] In the above formulas,
[260] Z ⁷ is a leaving group.
[261] 6. A compound of formula (I) wherein Y is C = N (CN) is prepared by reacting a compound of formula (XXIX) with a compound of formula (II) and then reacting the intermediate of formula (XXIVB) obtained with an amine of formula R ³ R ⁴ NH Can be:
[262] Z ⁸ C = N (CN) .Z ⁹
[263]
[264] In the above formulas,
[265] Z ⁸ and Z ⁹ are each the same or different leaving groups and can be, for example, -S (C ₁ -C ₆ alkyl), preferably -SCH ₃ .
[266] In a typical process, a solution of the compound of formula II in a suitable solvent such as ethanol is reacted with dimethylcyanothioimidocarbamate, preferably at room temperature. At the end of the reaction an amine of formula R ³ R ⁴ NH is then added and the reaction mixture is preferably heated under reflux to afford the desired product.
[267] 7. Any compound of formula (I) may be reacted with a amine of formula (XVIII) with a compound of formula (XIV) under a selective pressure in an optional inert solvent such as 1,2-dimethoxyethane or 2-methoxyethyl Can be prepared by reaction:
[268] Formula XVIII
[269] R ¹⁵ NH-X-NR ² -Y-NR ³ R ⁴
[270] Preferably, the reaction is carried out in the absence of solvent at a temperature of 100 to 120 ° C.
[271] All reactions used in the above methods and the preparation of new starting materials are conventional methods, and methods for isolating the desired product as well as the appropriate reagents and reaction conditions for performance or preparation are given in the literature and in the examples and preparations below. It is well known to those skilled in the art with reference to. In particular, suitable protection and deprotection methods are well known in the art, for example as described in Greene et al., "Protective Groups Organic Synthesis", Third Edition, John Wiley & Sons Ltd.
[272] Pharmaceutically acceptable salts of compounds of formula (I) can be readily prepared by mixing together solutions of the compounds of formula (I) with the desired acid or base, if desired. The salt may precipitate out of solution and be collected via filtration or may be recovered by evaporation of the solvent.
[273] The anti-inflammatory properties of the compounds of formula (I) are evidenced by their ability to inhibit the function of neutrophils showing A2a receptor agonist activity. This ability is assessed by measuring the profile of the compound in an assay that determines whether superoxide is produced from neutrophils activated with fMLP. Neutrophils were isolated from human peripheral blood using dextran sedimentation and then centrifuged in Ficoll-Hypaque solution. Any contaminating red blood cells in the granulocyte pellets were dissolved by dissolving with ice cold distilled water. The production of superoxide from neutrophils was induced by fMLP in the presence of an initiator concentration of cytokalcin B. Adenosine deaminase has been used in this assay to remove any endogenously produced adenosine that can inhibit the production of superoxides. The effect of the compounds of the present invention on the reaction induced by fMLP was observed colorimetrically from reduction of cytochrome C in assay buffer. The efficacy of the compounds of the invention was assessed at concentrations at which 50% was inhibited (IC ₅₀ ) compared to the response of the control to fMLP.
[274] The compounds of formula (I) may be administered alone, but are generally administered in admixture with appropriate pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.
[275] For example, the compounds of formula (I) can be administered orally, buccally or sublingually in the form of tablets, capsules, various microparticles, gels, films, suppositories, elixirs, solutions or suspensions, Flavoring or coloring agents may be included for delayed-release, sustained release, pulse-release or controlled-release applications. In addition, the compounds of formula (I) can be administered in the form of high dispersions or in dosage forms which disperse or dissolve rapidly, or as coated particles. Suitable formulations of the compounds of formula (I) may optionally be in the form of coated or uncoated.
[276] Such solid pharmaceutical compositions, e.g. tablets, include excipients (e.g. microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dicalcium phosphate, glycine and starch (preferably corn, potato or tapioca starch)), disintegrants (Eg sodium glycolate starch, croscarmellose sodium and certain silicate complexes) and granulation binders (eg polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) ), Sucrose, gelatin and acacia). Lubricants such as magnesium stearate, sodium stearyl fumarate, sodium lauryl sulfate, stearic acid, glyceryl behenate and talc may also be included.
[277] General example
[278] Formulations of tablets typically comprise 0.01 to 500 mg of active compound, while the fill weight of tablets can range from 50 to 1000 mg. Examples of formulations for 10 mg tablets are shown below:
[279] ingredient % (Weight / weight) Compound or salt of formula (I) 10.000 ^*Lactose 64.125 Starch 21.375 Croscarmellose sodium 3.000 Magnesium stearate 1.500 * Amount is adjusted according to drug activity
[280] Tablets may be prepared by standard methods, such as direct compression, or by wet or dry granulation methods. Tablet cores may be coated with a suitable protective coating.
[281] In addition, solid compositions of a similar type can also be used as fillers in gelatin or HPMC capsules. In this regard, preferred excipients include lactose, starch, cellulose, lactose or high molecular weight polyethylene glycols. In the case of aqueous suspensions and / or elixirs, the compounds of formula (I) are combined with various sweetening or flavoring agents, colorants or dyes and combined with emulsifiers and / or suspending agents and diluents (e.g. water, ethanol, propylene glycol or glycerin). And mixtures thereof).
[282] In addition, the compounds of formula (I) may be administered parenterally (eg, intravenously, intraarterally, intraperitoneally, intradural, intraventricularly, intraurethally, intrasternally, intracranially, intramuscularly or subcutaneously), or Administration may be by infusion technique without the use of infusions or needles. For such parenteral administration, the compounds are best used in the form of sterile aqueous solutions which may contain other substances (e.g., co-solvents, and / or sufficient salts or glucose to make the solution isotonic with blood). . The aqueous solution should be buffered appropriately (preferably to pH 3-9) as needed. Suitable parenteral formulations under sterile conditions are readily prepared by standard pharmaceutical techniques well known to those skilled in the art.
[283] When administered orally and parenterally to human patients, the daily dosage of the compound of formula (I) will typically be from 0.00001 to 100 mg, preferably from 0.0001 to 100 mg (in single or divided doses) per kg of body weight.
[284] Thus, tablets or capsules of the compound of formula (I) may optionally comprise from 5 to 500 mg of the active compound for administration one or more times at a time. In either case, the attending physician will determine the actual dosage that is most appropriate for any individual patient, which dosage will vary depending on the age, weight and response of the particular patient. The above dosage is an example of an average case. Of course, there may be individual examples in which higher or lower dosage ranges are effective, and such cases are also within the scope of the present invention.
[285] In addition, the compounds of formula (I) may be administered intranasally or by inhalation, and may contain suitable propellants (eg, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, hydrofluoroalkanes (eg, For example, 1,1,1,2-tetrafluoroethane (HFA 134A®) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA®) ), Delivered in the form of a dry powder inhaler, with or without carbon dioxide, perfluorinated hydrocarbons (eg, Perflubron®) or other suitable gases), or pressurized vessels, It is conveniently delivered in the form of aerosol spray from a pump, nebulizer, atomiser or nebuliser. In the case of a pressurized aerosol, the dosage unit can be measured using a valve that carries a metered amount. Pressurized vessels, pumps, nebulizers, atomizers or nebulizers can be used, for example, with ethanol (optionally aqueous ethanol), or with a suitable dispersant, solubilizer or extender and a mixture of propellants (such solvents are lubricants, for example trioleic acid). Sorbitan may be further included) or a solution or suspension of the active compound. Capsules, blowing agents and cartridges (e.g., made of gelatin or HPMC) for use in inhalers or blowers are those of the formula I, suitable powder bases (e.g. lactose or starch) and performance modifiers (e.g. For example, it may be formulated to include a powder mixture of L-leucine, mannitol or magnesium stearate).
[286] Suitable solution formulations for use in atomizers using electrofluidics to produce fine mists can include from 1 μg to 1 mg of a compound of formula (I) or a salt thereof, with actuation volumes varying from 1 to 100 μl. can do. Typical formulations may comprise a compound of formula (I) or a salt thereof, propylene glycol, sterile water, ethanol and sodium chloride.
[287] Aerosol or dry powder formulations are preferably prepared such that each of the metered doses or “puffs” comprises from 1 to 4000 μg of the compound of formula (I) for delivery to the patient. The total daily dose of aerosol will range from 1 μg to 20 mg and may be administered once a day, or more generally, several times a day.
[288] Alternatively, the compounds of formula (I) may be administered in the form of suppositories or pessaries, or may be applied topically in the form of lotions, solutions, creams, ointments or dispersants. The compounds of formula (I) may also be applied to the skin or transdermally using skin patches. In addition, they may be administered by the pulmonary, vaginal or rectal route.
[289] When applied topically to the skin, the compound of formula (I) is for example in a mixture selected from at least one of the group consisting of mineral oil, petroleum jelly, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water It may be formulated as a suitable ointment comprising the active compound suspended or dissolved. Alternatively, the compound consists, for example, of mineral oil, sorbitan monostearate, polyethylene glycol, paraffinic liquid, polysorbate 60, cetyl ester wax, cetylaryl alcohol, 2-octyldodecanol, benzyl alcohol and water It may be formulated into a suitable lotion or cream suspended or dissolved in one or more selected mixtures from the group.
[290] In addition, the compounds of formula (I) can be used in admixture with cyclodextrins. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of the drug-cyclodextrin complex can modify the solubility, dissolution rate, bioavailability and / or stability characteristics of the drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. Cyclodextrins may be used as auxiliary additives (eg, carriers, diluents or solubilizers) instead of forming complexes directly with the drug. Alpha-, beta- and gamma-cyclodextrins are most commonly used, suitable examples of which are described in WO-A-91 / 11172, WO-A-94 / 02518 and WO-A. -98/55148.
[291] All references to treatment herein will be understood to include therapeutic, palliative, prophylactic treatments.
[292] Therefore, the present invention
[293] (i) a compound of Formula (I), or a pharmaceutically acceptable salt or solvent compound thereof;
[294] (ii) a process for preparing a compound of formula (I), or a pharmaceutically acceptable salt or solvent compound thereof;
[295] (iii) a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvent compound thereof, together with a pharmaceutically acceptable excipient, diluent or carrier;
[296] (iv) a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound, or composition thereof, for use as a medicament;
[297] (v) the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of a medicament having A2a receptor agonist activity;
[298] (vi) the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of an anti-inflammatory agent;
[299] (vii) the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of a medicament for the treatment of respiratory disease;
[300] (viii) the use according to (vii) above, wherein the disease is selected from the group consisting of adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchodilation, chronic sinusitis and rhinitis ;
[301] (ix) septic shock, male impotence, male factor infertility, female factor infertility, hypertension, stroke, epilepsy, cerebral ischemia, peripheral vascular disease, post-ischemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis To treat gastrointestinal damage or psychotic disorders caused by allergic dermatitis, eczema, ulcerative colitis, Crohn's disease, inflammatory bowel disease, Helicobacter pylori gastritis, non-Helicobacter pilori gastritis, nonsteroidal anti-inflammatory drugs, or wounds The use of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of a medicament for the treatment of thyroid;
[302] (x) treating a mammal, including a human, with an A2a receptor agonist, comprising treating the mammal with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvent compound, or composition thereof;
[303] (xi) A method of treating a mammal, including a human, to treat an inflammatory disease, comprising treating the mammal with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof. ;
[304] (xii) a method of treating a mammal, including a human, for treating a respiratory disease, comprising treating the mammal with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof ;
[305] (xiii) the method according to xii above, wherein the disease is selected from the group consisting of adult respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchiectasis, chronic sinusitis and rhinitis;
[306] (xiv) septic shock, male erectile dysfunction, male factor infertility, female factor infertility, comprising treating a mammal with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, Hypertension, stroke, epilepsy, cerebral ischemia, peripheral vascular disease, post-ischemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis, allergic dermatitis, eczema, ulcerative colitis, Crohn's disease, inflammatory bowel disease, Helicobacter Methods of treating mammals, including humans, to treat gastrointestinal damage or psychotic disorders caused by phyllori gastritis, non-Helicobacter phyllori gastritis, nonsteroidal anti-inflammatory drugs, or to heal wounds; And
[307] (xv) certain novel intermediates disclosed herein
[308] To provide.
[309] As used in the following Examples and Preparation Examples, "THF" means tetrahydrofuran, "DMSO" means dimethylsulfoxide, and "TLC" means thin layer chromatography.
[310] The following examples illustrate the preparation of compounds of formula (I).
[311] Example 1
[312] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N- {2-[({[2- (1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[313]
[314] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 10) (90 mg, 0.15 mmol) and N- [2- (1-piperidinyl) ethyl]- 1H-imidazole-1-carboxamide (Preparation 18) (36 mg, 0.16 mmol) was dissolved in dichloromethane (3 mL). Toluene (4 mL) and isopropanol (1 mL) were added and evaporated at atmospheric pressure to remove dichloromethane. The remaining solution was heated at reflux for 4 hours. TLC analysis showed that the reaction was incomplete and additional N- [2- (1-piperidinyl) ethyl] -1H-imidazole-1-carboxamide (25 mg, 0.11 mmol) was added and continued for 4 hours. Heated. The residue was purified by silica gel column chromatography eluting with dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 90: 10: 1) under reduced pressure. Fractions containing the product were evaporated and the resulting solid was triturated with diethyl ether and dried to give the title compound (60 mg) as a white powder.
[315]
[316] Example 2
[317] N- {2-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] ethyl} -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[318]
[319] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 10) (90 mg, 0.16 mmol) and N- [2- (diisopropylamino) ethyl] -1 H Imidazole-1-carboxamide (Preparation 19) (40 mg, 0.17 mmol) was dissolved in dichloromethane (3 mL). Toluene (4 mL) and isopropanol (1 mL) were added and evaporated at atmospheric pressure to remove dichloromethane. The residual solution was then heated at reflux for 4 hours. TLC analysis showed that the reaction was incomplete, adding additional N- [2- (diisopropylamino) ethyl] -1H-imidazole-1-carboxamide (30 mg, 0.13 mmol) and continuing to add for 4 hours Heated to. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 90: 10: 1) to give the title compound (60 mg) as a white solid.
[320]
[321] Example 3
[322] 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[(2,2-diphenylethyl) amino ] -N- {2-[({[2- (1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[323]
[324] N- (2-aminoethyl) -9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[( 2,2-diphenylethyl) amino] -9H-purine-2-carboxamide (Preparation 17) (90 mg, 0.17 mmol) and N- [2- (1-piperidinyl) ethyl] -1 H-already Dazole-1-carboxamide (Preparation Example 18) (40 mg, 0.18 mmol) was dissolved in a mixture of toluene (4 mL) and isopropanol (1 mL) and the solution was heated at reflux for 4 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 85: 15: 1.5). Fractions containing product were evaporated and the resulting solid was triturated with diethyl ether, filtered and dried to give the title compound (85 mg) as a white powder.
[325]
[326] Example 4
[327] 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -N- {2-[({[2-diiso Propylamino) ethyl] amino} carbonyl) amino] ethyl} -6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxamide
[328]
[329] N- (2-aminoethyl) -9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[( 2,2-diphenylethyl) amino] -9H-purine-2-carboxamide (Preparation 17) (90 mg, 0.17 mmol) and N- [2- (diisopropylamino) ethyl] -1 H-imidazole -1-Carboxamide (Preparation 19) (50 mg, 0.19 mmol) was dissolved in a mixture of toluene (4 mL) and isopropanol (1 mL) and the solution was heated at reflux for 4 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 85: 15: 1.5). Fractions containing product were evaporated and the resulting solid was triturated with diethyl ether, filtered and dried to give the title compound (85 mg) as a white powder.
[330]
[331] Example 5
[332] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N- {2-[({[2- (4-isopropyl-1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[333]
[334] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation Example 10) and N- [2- (4-isopropyl-1-piperidinyl) ethyl] -1H The title compound was prepared in a similar manner to Example 1 using imidazole-1-carboxamide (Preparation 22) as starting material.
[335]
[336] Example 6
[337] N- (2-{[({2- [cyclopentyl (isopropyl) amino] ethyl} amino) carbonyl] amino} ethyl) -6-[(2,2-diphenylethyl) amino] -9- { (2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[338]
[339] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) 5-[(ethylamino) carbonyl] -3,4 -Dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 10) and N- {2- [cyclopentyl (isopropyl) amino] ethyl} -1 H-imidazole The title compound was prepared in a similar manner to Example 1 using -1-carboxamide (Preparation 26) as the starting material.
[340]
[341] Example 7
[342] N- (2-{[({2- [cyclohexyl (isopropyl) amino] ethyl} amino) carbonyl] amino} ethyl) -6-[(2,2-diphenylethyl) amino] -9- { (2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[343]
[344] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 10) and N- {2- [cyclohexyl (isopropyl) amino] ethyl} -1H-imidazole The title compound was prepared in a similar manner to Example 1 using -1-carboxamide (Preparation 29) as starting material.
[345]
[346] Example 8
[347] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N- {2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[348]
[349] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 10) and N- [1- (2-pyridinyl) -4-piperidinyl] -1H- The title compound was prepared in a similar manner to Example 1 using imidazole-1-carboxamide (Preparation 30) as the starting material.
[350]
[351] Examples 9 to 27
[352] The compounds of the examples set forth in the table below were prepared in a similar manner to Example 1 using the appropriate amines and imidazolides as starting materials.
[353] Table 1 shows the structure of the compounds and Table 2 shows the analytical data for each compound.
[354] The term "n-Bu" in Table 1 means n-butyl.
[355] Imidazolide starting materials for Examples 13, 24 and 25 are described in J. Chem. Soc. Perkin Trans. 1, 11, 1205, 1996, as described herein.
[356] Imidazolide starting materials for Example 15 are described in Jutus Liebgs Ann. Cmem., 648, 72, 1961.
[357]
[358]
[359]
[360]
[361]
[362]
[363]
[364]
[365]
[366]
[367]
[368]
[369] Example 28
[370] (2S, 3S, 4R, 5R) -5- {2-({(3R) -3-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] pyrrolidinyl} -carbon Nil) -6-[(2,2-diphenylethyl) amino] -9H-purin-9-yl} -N-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide
[371]
[372] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4- in dichloromethane (5 mL) Dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxylic acid (Example 39) (200 mg, 0.37 mmol), N- [2- (diisopropylamino) ethyl] -N '-[( 3R) -pyrrolidinyl] urea (Preparation 44) (106 mg, 0.41 mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (79 mg, 0.41 mmol) and 1-hydroxybenzo A solution of triazole (5 mg, 0.037 mmol) was stirred at rt for 14 h. Water (1 mL) was added and the organic layer was separated. The aqueous phase was extracted two more times with dichloromethane (1 mL) and the combined extracts were dried over anhydrous magnesium sulfate. Silica gel column chromatography evaporating the solvent under reduced pressure and eluting with a gradient system changing from dichloromethane: methanol: rich aqueous ammonia (volume ratio 90: 10: 1) to dichloromethane: methanol: condensed aqueous ammonia (volume ratio 80: 20: 1). The residue was purified by. After evaporation of the appropriate fractions the residue was triturated with diethyl ether, filtered and dried to afford the desired compound (0.1 g, 35%) as a white solid.
[373]
[374] Example 29
[375] (2S, 3S, 4R, 5R) -5- {2-({(3S) -3-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] pyrrolidinyl} -carbon Nil) -6-[(2,2-diphenylethyl) amino] -9H-purin-9-yl} -N-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide
[376]
[377] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 Furanyl} -9H-purin-2-carboxylic acid (Preparation Example 39) and N- [2- (diisopropylamino) ethyl] -N '-[(3S) -pyrrolidinyl] urea (Preparation 45) The title compound was prepared in the same manner as in Example 28 using, as a starting material. The title compound was obtained as white powder.
[378]
[379] Example 30
[380] 6-{[2,2-bis (3-methylphenyl) ethyl] amino} -N- {2-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] ethyl} -9- {(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[381]
[382] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-{[2,2-bis (3-methylphenyl) ethyl] amino} -2-iodo- in THF (5 mL) 9H-purin-9-yl) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate (Preparation 48) (200 mg, 0.24 mmol), N- (2-aminoethyl) -N A solution of '-[2- (diisopropylamino) ethyl] urea (Preparation 52) (270 mg, 1.18 mmol) and tetrakis (triphenylphosphine) palladium (0) (27 mg, 0.024 mmol) was prepared using a carbon monoxide atmosphere ( 345 KPa) at 60 ° C. for 14 hours. Analysis by TLC showed the desired product with partially deprotected material. The solvent was evaporated under reduced pressure to completely remove the benzoate protecting group, the residue was dissolved in methanol (10 mL), sodium carbonate (10 mg) was added and the mixture was stirred at rt for 24 h. Purify the residue under reduced pressure and purify the residue by silica gel column chromatography eluting with a gradient system that changes from dichloromethane: methanol (volume ratio 90:10) to dichloromethane: methanol: concent aqueous ammonia (volume ratio 90: 10: 1). It was. After evaporation of the appropriate fractions, the residue was triturated with diethyl ether, filtered and dried to afford the desired compound (0.11 g, 61%) as a white solid.
[383]
[384] Example 31
[385] 6-{[2,2-bis (3-chlorophenyl) ethyl] amino} -N {2-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] ethyl} -9- {(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[386]
[387] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-{[2,2-bis (3-chlorophenyl) ethyl] amino} -2-iodo-9H-purine-9 -Yl) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate (Preparation 49) and N- (2-aminoethyl) -N '-[2- (diisopropylamino) The title compound was prepared in a similar manner to Example 30 using ethyl] urea (Preparation 52) as a starting material. The desired compound was obtained as a white solid.
[388]
[389] Example 32
[390] 6-{[2,2-bis (3-chlorophenyl) ethyl] amino} -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydro Loxytetrahydro-2-furanyl} -N- {2-[({[2- (1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[391]
[392] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-{[2,2-bis (3-chlorophenyl) ethyl] amino} -2-iodo-9H-purine-9 -Yl) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate (Preparation 49) and N- (2-aminoethyl) -N '-[2- (1-piperidinyl The title compound was prepared in a similar manner to Example 30 using) ethyl] urea (Preparation 53) as starting material. The desired compound was obtained as a white solid.
[393]
[394] Example 33
[395] 6-{[2,2-bis (3-methylphenyl) ethyl] amino} -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxy Tetrahydro-2-furanyl} -N- {2-[({[2- (1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[396]
[397] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-{[2,2-bis (3-methylphenyl) ethyl] amino} -2-iodo-9H-purine-9- Yl) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate (Preparation 48) and N- (2-aminoethyl) -N '-[2- (1-piperidinyl) The title compound was prepared in a similar manner to Example 30 using ethyl] urea (Preparation 53) as a starting material. The desired compound was obtained as a white solid.
[398]
[399] Example 34
[400] 4-[({[(2-{[(6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purin-2-yl) carbonyl] amino} ethyl) amino] carbonyl} amino) methyl] benzoic acid
[401]
[402] Benzyl 4-[({[(2-{[(6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5- [in ethanol (10 mL)) (Ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purin-2-yl) carbonyl] amino} ethyl) amino] carbonyl} amino) methyl] benzoate Preparation 55) A solution of (150 mg, 0.18 mmol) was hydrogenated at 10% (weight / weight) palladium on carbon (30 mg) and 414 kPa for 28 hours at new temperature. The catalyst was removed by filtration with Arbocel® and the solvent was evaporated under reduced pressure to yield the title compound (26 mg) as a white powder.
[403]
[404] Example 35
[405] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S)-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-fura Nyl} -N- {2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[406]
[407] 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3 in pure ethanol (200 mL) ] Dioxol-4-yl} -6-[(2,2-diphenylethyl) amino] -N- {2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} To a solution of carbonyl) amino] ethyl} -9H-purine-2-carboxamide (Preparation 71) (20.9 g, 0.0255 mol) was added 1M aqueous hydrochloric acid (76.5 mL, 0.0765 mol) and the resulting solution was 60 Heated to 65 ° C. for 24 h. The reaction mixture was cooled to ambient temperature and saturated aqueous sodium bicarbonate solution (200 mL) was added carefully. The resulting mixture was then concentrated in vacuo and then the aqueous mixture was extracted with ethyl acetate (200 mL) followed by dichloromethane (200 mL). The extract was dried over anhydrous magnesium sulfate to give a gum deposit which was redissolved by addition of dichloromethane (100 mL) and methanol (20 mL). The resulting purple solution was then concentrated in vacuo to afford the crude product as a purple foam (20.86 g) and methanol in dichloromethane (6% volume / volume) was added methanol in dichloromethane (8% volume / volume), dichloromethane Purification by chromatography on silica gel (600 g) eluting with a gradient changing to methanol in water (10% volume / volume) and methanol in dichloromethane (15% volume / volume) yielded the title compound in several fractions of varying purity. It was. The main fraction (11.4 g) was dissolved in dichloromethane (264 mL) and filtered to remove insoluble matters. Diethyl ether (112 mL) was added to this solution and the resulting cloudy mixture was stirred at ambient temperature for 1 hour. The solid was then collected by filtration and dried under vacuum. The material was then ground using a mortar and pestle and further dried at 50 ° C. in vacuo to yield the title compound (9.9 g) as a fine colorless powder.
[408]
[409] Obtaining ¹ H NMR spectra at 70 ° C. causes the signal that is responsible for one or more isoforms to disappear at 30 ° C.
[410] The following preparations describe the preparation of the particular intermediates used in the examples described above.
[411] Preparation Example 1
[412] 2,6-dichloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purine
[413]
[414] 2,6-dichloro-9H-purine (20 g, 0.11 mol) and 4-toluenesulfonic acid monohydrate (0.2 g) were dissolved in ethyl acetate (300 mL), the mixture was heated to 50 ° C. and ethyl acetate (50 mL) A solution of 3,4-dihydro-2H-pyran (12.6 mL, 0.14 mol) in water was added slowly over 30 minutes. The reaction mixture was cooled to room temperature, water (100 mL) was added and the saturated pH solution was added to adjust the solution to pH 7. The organic layer was separated and washed successively with water and brine, dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure. The residue was azeotroduced twice with pentane to afford the title compound as a slightly impure white solid (30.9 g).
[415]
[416] Preparation Example 2
[417] 2-Chloro-N- (2,2-diphenylethyl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-amine
[418]
[419] A solution of 2,6-dichloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purine (Preparation Example 1) (30.9 g, 0.11 mol) in isopropyl alcohol (600 mL) was diluted with N-ethyl. React with -N-isopropyl-2-propanamine (47.5 mL, 0.27 mol) and 2,2-diphenylethylamine (24.8 g, 0.13 mol) and heat the resulting mixture under reflux for 3 hours. The solvent was removed under reduced pressure and the residue was azeotropic with ethyl acetate. Purify the residue by silica gel column chromatography, eluting with a gradient system which gradually changes from ethyl acetate: hexane (volume ratio 40:60) to ethyl acetate: hexane (volume ratio 60:40) to give the title compound (49.7 g) as a foam. It was.
[420]
[421] Preparation Example 3
[422] N- (2,2-diphenylethyl) -2- (methylsulfanyl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-amine
[423]
[424] 2-Chloro-N- (2,2-diphenylethyl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6- in anhydrous N, N-dimethylformamide (200 mL) A solution of amine (Preparation 2) (49.7 g, 0.11 mol) was reacted with sodium thiomethoxide (10 g, 0.14 mol) and the reaction mixture was heated at 100 ° C. for 90 minutes under a nitrogen atmosphere. The mixture was stirred at rt for 72 h and then heated at 100 ° C. for a further 2 h. The reaction mixture was cooled down and diluted with water (1000 mL). The resulting suspension was extracted twice with diethyl ether. The combined organic layers were washed successively with water and brine, dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure. The residue was azeotropic with diethyl ether and then with pentane to give the title compound (48.9 g) as a foam.
[425]
[426] Preparation Example 4
[427] N- (2,2-diphenylethyl) -2- (methylsulfonyl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-amine
[428]
[429] A solution of Oxone (registered trademark) (potassium peroxymonosulfate) (44 g, 71.7 mmol) in water (200 mL) was added with N- (2,2-diphenyl in acetone (1000 mL) and water (250 mL). Ethyl) -2- (methylsulfanyl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-amine (Preparation 3) (25 g, 56.2 mmol) and sodium hydrogen carbonate (20 g , 238 mmol) was added dropwise over 2 hours. The resulting mixture was stirred at rt for 24 h, filtered and the residue was washed with acetone. Acetone was removed from the filtrate under reduced pressure and the resulting aqueous residue was extracted with ethyl acetate and then extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure. The residue was triturated with diethyl ether, filtered, washed with diethyl ether and pentane and dried to afford the title compound (20.32 g) as a white solid.
[430]
[431] Preparation Example 5
[432] 6-[(2,2-diphenylethyl) amino] -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-2-carbonitrile
[433]
[434] N- (2,2-diphenylethyl) -2- (methylsulfonyl) -9- (tetrahydro-2H-pyran-2-yl) -9H- in anhydrous N, N-dimethylformamide (100 mL) A solution of Purin-6-amine (Preparation 4) (20.1 g, 42.1 mmol) was reacted with potassium cyanide (5.5 g, 84.6 mmol) and the mixture was heated at 120 ° C. for 24 h under a nitrogen atmosphere. The mixture was cooled to rt, poured into water (1000 mL) and stirred for a further hour. The resulting solid was filtered off and washed several times with water. The solid was then dissolved in dichloromethane and the solution washed with water, dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure. The residue was azeotroduced twice with diethyl ether to afford the title compound as an oil (17 g).
[435]
[436] Preparation Example 6
[437] 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carbonitrile
[438]
[439] 6-[(2,2-diphenylethyl) amino] -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-2-carbonitrile (Preparation 5) in ethanol (850 mL) ( 17 g, 40.1 mmol) was reacted with 2N aqueous hydrochloric acid (50 mL) and the mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure and the residue was dissolved in ethanol and the solvent was removed again under reduced pressure. The residue was triturated with diethyl ether, filtered, washed with diethyl ether and pentane and dried to give the title compound (13.6 g) as a solid.
[440]
[441] Preparation Example 7
[442] Methyl 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate
[443]
[444] 6-[(2,2-diphenylethyl) amino] -9H-purin-2-carbonitrile (Preparation 6) (5.0 g, 14.7 mmol) and sodium methoxide (4.0 g, 74.1) in methanol (300 mL) mmol) was heated at reflux for 24 h. Further sodium methoxide (2.0 g, 37 mmol) and methanol (100 mL) were added and heated further successively for 24 hours. The reaction mixture was cooled down and the solvent was removed under reduced pressure. Dissolved in tetrahydrofuran (THF) (375 mL) and 2N aqueous hydrochloric acid (125 mL) was added and the mixture was stirred at rt for 24 h. THF was removed under reduced pressure and the suspension was basified to pH 7 using saturated aqueous sodium bicarbonate solution. Ethyl acetate (100 mL) was added and the white solid consisting mainly of the desired product was filtered off, washed with some water and ethyl acetate and dried. Purification by silica gel column chromatography eluting with a gradient system that gradually changes from dichloromethane: methanol (volume ratio 90:10) to dichloromethane: methanol (volume ratio 75:25) yields the title compound (1.25 g, 25%) as a white solid. Obtained. Ethyl acetate filtrate was evaporated to give starting material (2.6 g).
[445]
[446] Preparation Example 8
[447] Methyl 9-{(2R, 3R, 4R, 5S) -3,4-bis (benzoyloxy) -5-[(ethylamino) carbonyl] tetrahydro-2-furanyl} -6-[(2,2 -Diphenylethyl) amino] -9H-purine-2-carboxylate
[448]
[449] Of methyl 6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylate (Preparation Example 7) (440 mg, 1.18 mmol) in 1,1,1-trichloroethane (25 mL) The mixture was reacted with N, O-bis (trimethylsilyl) acetamide (1.7 mL, 6.95 mmol). The mixture was heated at reflux for 1 h. The solution was cooled to rt and the solvent was removed under reduced pressure. The residue was washed with (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -5- (acetyloxy) -4- (benzoyloxy) -2-[(ethyl in anhydrous toluene (25 mL). amino) carbonyl] tetrahydro-3-furanyl benzo the byte (Preparation 14) (620mg, 1.4 mmol) solution and then reacting trimethylsilyl trifluoroacetate was reacted with methane sulfonate (0.26㎖, 1.42 mmol) of . The resulting solution was then heated at 110 ° C. for 2.5 hours under a nitrogen atmosphere. The mixture was cooled to room temperature, diluted with ethyl acetate (200 mL) and washed with saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure. Purification of the residue by silica gel column chromatography eluting with a gradient method from dichloromethane: ethyl acetate (volume ratio 5: 1) to dichloromethane: ethyl acetate (volume ratio 1: 1) gave the title compound (540 mg, 60%) as a foam. Obtained.
[450]
[451] Preparation Example 9
[452] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- 2-furanyl} -9H-purine-2-carboxylate
[453]
[454] Methyl 9-{(2R, 3R, 4R, 5S) -3,4-bis (benzoyloxy) -5-[(ethylamino) carbonyl] tetrahydro-2-furanyl}-in anhydrous methanol (60 mL) A solution of 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate (Preparation Example 8) (3.4 g, 4.5 mmol) and sodium carbonate (50 mg) was stirred at room temperature for 4 hours. . The solvent was removed under reduced pressure and the residue was dissolved in a mixture of dichloromethane: methanol (volume ratio 95: 5, 60 mL). The inorganic salts were filtered off and the filtrate was evaporated under reduced pressure. The residue was triturated with diethyl ether, filtered off and dried to give the title compound (2.4 g, 98%) as a white solid.
[455]
[456] Preparation Example 10
[457] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[458]
[459] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- A mixture of 2-furanyl} -9H-purine-2-carboxylate (Preparation 9) (1.1 g, 2 mmol) and 1,2-ethylenediamine (1.1 g, 18.3 mmol) was heated at 105 ° C. for 2.5 hours. It was. The mixture was dissolved in some dichloromethane and the residue was purified by silica gel column chromatography eluting with dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 85: 15: 1.5). After evaporation of the appropriate fractions the residue was triturated with diethyl ether, filtered and dried to give the title compound (0.99 g, 86%) as a white solid.
[460]
[461] Preparation Example 11
[462] (3aS, 4S, 6R, 6aR) -N-ethyl-6-methoxy-2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-carboxamide
[463]
[464] Oxalyl chloride (14.0 mL, 160 mmol) was added (3aR, 4S, 6R, 6aR) -6-methoxy-2,2- in anhydrous dichloromethane (120 mL) and N, N-dimethylformamide (2 drops). Dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-carboxylic acid (see J. Amer. Chem. Soc. , 80 , 5168-5173, 1958) (23.30 g, 107 mmol) ) Was added dropwise to the stirred solution and the mixture was stirred at room temperature for 3 hours until gas evolution ceased. As a result of analysis by TLC, some starting material remained so that additional N, N-dimethylformamide (2 drops) was added and stirring continued for 1 hour. The solvent was removed under reduced pressure and the residue was azeotroduced twice with anhydrous dichloromethane. The residue was dissolved in anhydrous dichloromethane (200 mL) and the solution was reacted dropwise with ethylamine (2M solution in tetrahydrofuran, 140 mL, 280 mmol). The solution was left for 48 hours at room temperature. Diethyl ether (250 mL) was added and the mixture was stirred for 15 minutes. The mixture was filtered and the solvent was removed from the filtrate under reduced pressure. The residue was purified by silica gel column chromatography eluting with a gradient system which gradually changed from dichloromethane to dichloromethane: ethylacetate (volume ratio 44:66) to afford the title compound (24.70 g) as a yellow solid.
[465]
[466] Preparation Example 12
[467] (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -N-ethyl-3,4-dihydroxy-5-methoxytetrahydro-2-furancarboxamide
[468]
[469] (3aS, 4S, 6R, 6aR) -N-ethyl-6-methoxy-2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4- in methanol (500 mL) A solution of carboxamide (Preparation 11) (24.60 g, 100 mmol) and pyridinium p-toluenesulfonate (2.50 g, 10 mmol) was heated at reflux for 18 h. As a result of analysis by NMR, some starting material still remained to remove the solvent under reduced pressure. The residue was dissolved in methanol (500 mL) and heated at reflux for 8 h. As a result of analysis by NMR, some starting material still remained, so that the solvent was removed under reduced pressure, and the residue was dissolved in methanol (500 mL) and heated at reflux for 24 hours. The solvent was removed under reduced pressure and the residue was azeotroduced three times with dichloromethane to afford the title compound (20.50 g) as an oil and a mixture of α and β anomers.
[470]
[471] Preparation Example 13
[472] (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -4- (benzoyloxy) -2-[(ethylamino) carbonyl] -5-methoxytetrahydro-3-furanyl Benzoate
[473]
[474] A solution of benzoyl chloride (30.0 mL, 259 mmol) in dichloromethane (100 mL) was added to (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -N-ethyl in dichloromethane (400 mL). To a solution of -3,4-dihydroxy-5-methoxytetrahydro-2-furancarboxamide (20.50 g, 100 mmol) and pyridine (33.0 mL, 409 mmol) was added slowly and the resulting mixture was added at room temperature. Stir for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between diethyl ether and 1M aqueous hydrochloric acid (300 mL). The layers were separated and the aqueous layer was reextracted with diethyl ether. The organic layers were combined and washed successively with water and brine, dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure. Purify the residue by silica gel column chromatography, eluting with a gradient system that gradually changes from dichloromethane: diethyl ether (volume ratio 95: 5) to dichloromethane: diethyl ether (volume ratio 80:20). The title compound (37.0 g) was obtained as a mixture of mers.
[475]
[476] Preparation Example 14
[477] (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -5- (acetyloxy) -4- (benzoyloxy) -2-[(ethylamino) carbonyl] tetrahydro-3- Furanyl benzoate
[478]
[479] (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -4- (benzoyloxy) -2 in a mixture of acetic acid (330 mL, 5.77 mol) and acetic anhydride (67 mL, 709 mmol) A solution of-[(ethylamino) carbonyl] -5-methoxytetrahydro-3-furanyl benzoate (Preparation 13) (37.0 g, 89.6 mmol) was cooled to -10 < 0 > C, followed by 12N aqueous hydrochloric acid (7.0 132 mmol) was added dropwise. The mixture was stirred for 18 hours and warmed to room temperature for 18 hours. After the mixture was cooled to 0 ° C., water (1000 ml) was slowly added to the mixture, followed by extraction three times with ethyl acetate (500 ml). The organic layers were combined and washed successively with water, saturated aqueous sodium hydrogen carbonate solution and brine, dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with a gradient system that gradually changed to diethyl ether: pentane (volume ratio 66:44) to diethyl ether. Purify the residue by silica gel column chromatography, eluting with a gradient system that gradually changes from dichloromethane: diethyl ether (volume ratio 95: 5) to dichloromethane: diethyl ether (volume ratio 90:10). The title compound (15.40 g) was obtained as a mixture.
[480]
[481] Preparation Example 15
[482] Methyl 9-{(2R, 3R, 4R, 5R) -3,4-bis (acetyloxy) -5-[(acetyloxy) methyl] tetrahydro-2-furanyl} -6-[(2,2 -Diphenylethyl) amino] -9H-purine-2-carboxylate
[483]
[484] Methyl 6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylate (Preparation Example 7) (1.5 g, 4.02 mmol) in 1,1,1-trichloroethane (40 mL) The suspension was reacted with N, O-bis (trimethylsilyl) acetamide (4.8 mL, 19.6 mmol). The mixture was heated at reflux for 2 hours. The solution was cooled to rt and the solvent was removed under reduced pressure. The residue was dissolved in anhydrous toluene (40 mL), 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (1.65 g, 5.19 mmol) and trimethylsilyl trifluoromethanesulfonate ( 0.98 mL, 5.43 mmol) was added. The resulting solution was heated under reflux for 3 hours under a nitrogen atmosphere. The mixture was cooled to room temperature, diluted with ethyl acetate (200 mL) and washed with saturated aqueous sodium hydrogen carbonate solution. The organic layers were separated, dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure. Purify the residue by silica gel column chromatography, eluting with a gradient system that gradually changes from ethyl acetate: pentane (volume ratio 70:30) to ethyl acetate: pentane (volume ratio 80:20) to give the title compound (2.05 g) as a foam. It was.
[485]
[486] Preparation Example 16
[487] Methyl 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[(2,2-diphenylethyl) Amino] -9H-purine-2-carboxylate
[488]
[489] Methyl 9-{(2R, 3R, 4R, 5R) -3,4-bis (acetyloxy) -5-[(acetyloxy) methyl] tetrahydro-2-furanyl} -6-[(2,2- A solution of diphenylethyl) amino] -9H-purine-2-carboxylate (Preparation Example 15) (2.0 g, 3.17 mmol), sodium carbonate (35 mg) and anhydrous methanol (40 mL) was stirred at room temperature for 3.5 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with a gradient system which gradually changed from dichloromethane: methanol (volume ratio 94: 6) to dichloromethane: methanol (volume ratio 92: 8) to give the title as a white powder. Compound (1.5 g) was obtained.
[490]
[491] Preparation Example 17
[492] N- (2-aminoethyl) -9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[( 2,2-diphenylethyl) amino] -9H-purine-2-carboxamide
[493]
[494] Methyl 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[(2,2-diphenylethyl ) Amino] -9H-purine-2-carboxylate (Preparation Example 16) (0.52 g, 1.03 mmol) and 1,2-ethylenediamine (0.6 g, 10 mmol) were heated at 105 ° C. for 3 hours. The mixture was dissolved in some dichloromethane and the residue was purified by silica gel column chromatography eluting with dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 85: 15: 1.5). After evaporation of the appropriate fractions the residue was triturated with diethyl ether, filtered and dried to give the title compound (0.43 g, 78%) as a white solid.
[495]
[496] Preparation Example 18
[497] N- [2- (1-piperidinyl) ethyl] -1 H-imidazole-1-carboxamide
[498]
[499] 2- (1-piperidinyl) ethylamine (1.28 g, 10 mmol) was added to a solution of N, N'-carbonyldiimidazole (1.62 g, 10 mmol) in THF (25 mL) at room temperature. The reaction mixture was stirred overnight and evaporated to remove solvent. The residue was partitioned between ethyl acetate (100 mL) and water (50 mL), the ethyl acetate layer was separated, washed with brine (30 mL) and dried over Na ₂ SO ₄ . The solvent was evaporated under reduced pressure to afford the title compound (1.8 g) as a white solid.
[500]
[501] Preparation Example 19
[502] N- [2- (diisopropylamino) ethyl] -1 H-imidazole-1-carboxamide
[503]
[504] N ', N'-diisopropyl-1,2-ethanediamine (1 g, 6.94 mmol) was added to a stirred solution of N, N'-carbonyldiimidazole (1.12 g, 6.94 mmol) in dichloromethane (50 mL). Add at room temperature. The reaction mixture was stirred for 1 h, diluted with dichloromethane (50 mL), washed with water (60 mL), dried over anhydrous magnesium sulfate and the solvent removed under reduced pressure. This gave the title compound (600 mg) as a white solid.
[505]
[506] Preparation Example 20
[507] 2- [2- (4-isopropyl-1-piperidinyl) ethyl] -1 H-isoindole-1,3 (2H) -dione
[508]
[509] 4-isopropylpiperidine (3.3 g, 20.2 mmol), N- (2-bromoethyl) phthalimide (5.4 g, 21.3 mmol), potassium carbonate (5.9 g, 45.45 mmol) and acetonitrile (100 mL ) Solution was heated at reflux for 2.5 h and then stirred at rt overnight. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic extracts were dried over Na ₂ SO ₄ and evaporated under reduced pressure to remove the solvent. The resulting oil was purified by silica gel column chromatography eluting with dichloromethane: diethyl ether (volume 50:50) followed by diethyl ether to dichloromethane to dichloromethane to afford the title compound (3.3 g).
[510]
[511] Preparation Example 21
[512] 2- (4-isopropyl-1-piperidinyl) ethylamine
[513]
[514] 2- [2- (4-isopropyl-1-piperidinyl) ethyl] -1 H-isoindole-1,3 (2H) -dione (Preparation Example 20) (3.2 g, 10.6 mmol) was diluted with ethanol (60 mL). Heated at reflux for 3 h in a 33% (w / w) solution of methylamine in. The solvent was removed under reduced pressure, further ethanol was added and the solvent removed again under reduced pressure. The residue was suspended in dichloromethane (100 mL) and the solid was filtered off. It was washed with dichloromethane (100 mL). The filtrate was evaporated under reduced pressure and the resulting oil was purified by silica gel column chromatography eluting with dichloromethane: methanol: 0.88 NH ₃ aqueous solution (volume ratio 90: 10: 1) to give a colorless oil. Bulb-bulb- to-bulb) distillation (150-160 ° C., 4 kPa) afforded the title compound (1.0 g, 55%).
[515]
[516] Preparation Example 22
[517] N- [2- (4-isopropyl-1-piperidinyl) ethyl] -1 H-imidazole-1-carboxamide
[518]
[519] The title compound was prepared in a similar manner to Preparation Example 19 using 2- (4-isopropyl-1-piperidinyl) ethylamine (Preparation 21) and N, N'-carbonyldiimidazole as starting materials.
[520]
[521] Preparation Example 23
[522] N-isopropylcyclopentanamine
[523]
[524] Pearlman catalyst (20% (w / w) palladium hydroxide on carbon) (1.5 g) was added to a solution of cyclopentylamine (15 mL, 0.21 mol) in acetone (200 mL). The reaction mixture was stirred under 414 kPa (60 psi) hydrogen gas atmosphere. After stirring for 16 hours, the reaction mixture was filtered through avocel and the solvent was removed under reduced pressure to give the title compound (15 mL) as a dilute oil.
[525]
[526] Preparation Example 24
[527] [Cyclopentyl (isopropyl) amino] acetonitrile
[528]
[529] To a solution of N-isopropylcyclopentanamine (11.43 g, 0.09 mol) (Preparation 23) in ethanol (60 mL) was added hydroxyacetonitrile (8.2 ml of a 70% (weight / weight) solution in water). Added. The reaction mixture was heated at reflux for 3 hours, cooled and the solvent was removed under reduced pressure. Purify the residue by silica gel column chromatography eluting with dichloromethane: methanol (volume ratio 98: 2) to afford the title compound (14.1 g) as a clear oil:
[530]
[531] Preparation Example 25
[532] N'-cyclopentyl-N'-isopropyl-1,2-ethanediamine
[533]
[534] Lithium aluminum hydride (66 mL of 1 molar solution in tetrahydrofuran, 0.066 mol) in [cyclopentyl (isopropyl) amino] acetonitrile (Preparation 24) (10 g, 0.66 mol) in tetrahydrofuran (100 mL) To a stirred solution of was added at 0 ° C. The reaction mixture was stirred at 0 ° C. for 20 minutes and then heated at reflux for 2 hours. The reaction mixture was cooled to room temperature and left overnight. The reaction mixture was cooled in an ice bath and reacted dropwise with 7.5% (w / w) aqueous sodium hydroxide solution (4.8 mL) followed by dropwise addition of water (7.4 mL). The solvent was removed under reduced pressure, and the residue was slurried with diethyl ether (200 mL) for 30 minutes and then filtered. The filtrate was evaporated under reduced pressure to afford the title compound (10.30 g) as a colorless oil.
[535]
[536] Preparation Example 26
[537] N- {2- [cyclopentyl (isopropyl) amino] ethyl} -1H-imidazole-1-carboxamide
[538]
[539] The title compound was prepared in a similar manner to Preparation Example 19 using N'-cyclopentyl-N'-isopropyl-1,2-ethanediamine (Preparation 25) and N, N'-carbonyldiimidazole as starting materials. It was.
[540]
[541] Preparation Example 27
[542] [Cyclohexyl (isopropyl) amino] acetonitrile
[543]
[544] The title compound was prepared in a similar manner to Preparation 24 using N-isopropylcyclohexylamine and hydroxyacetonitrile as starting materials.
[545]
[546] Preparation Example 28
[547] N'-cyclohexyl-N'-isopropyl-1,2-ethanediamine
[548]
[549] The title compound was prepared in a similar manner to Preparation 25 using [cyclohexyl (isopropyl) amino] acetonitrile (Preparation 27) as the starting material.
[550]
[551] Preparation Example 29
[552] N- {2- [cyclohexyl (isopropyl) amino] ethyl} -1H-imidazole-1-carboxamide
[553]
[554] The title compound was prepared in a similar manner to Preparation Example 19 using N'-cyclohexyl-N'-isopropyl-1,2-ethanediamine (Preparation Example 28) and N, N'-carbonyldiimidazole as starting materials. It was.
[555]
[556] Preparation Example 30
[557] N- [1- (2-pyridinyl) -4-piperidinyl] -1H-imidazole-1-carboxamide
[558]
[559] In a similar manner as in Preparation Example 19, using 1- (2-pyridinyl) -4-aminopiperidine (WO 99/65895) and N, N'-carbonyldiimidazole as starting materials The title compound was prepared.
[560]
[561] Preparation Example 31
[562] N- (3-aminopropyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[563]
[564] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- A mixture of 2-furanyl} -9H-purine-2-carboxylate (Preparation 9) (0.35 g, 0.64 mmol) and 1,3-diaminopropane (0.45 g, 6.1 mmol) was stirred at 100 ° C. for 3 hours. Heated. Silica gel dissolved in a slight dichloromethane and eluted with a gradient system that changed from dichloromethane: methanol: rich aqueous ammonia (volume ratio 80: 20: 1.2) to dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 88: 12: 2). Purification by column chromatography. After evaporation of the appropriate fractions the residue was triturated with diethyl ether, filtered and dried to give the title compound (0.22 g, 58%) as a white solid.
[565]
[566] Preparation Example 32
[567] Trans-N- (4-aminocyclohexyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[568]
[569] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- A mixture of 2-furanyl} -9H-purine-2-carboxylate (Preparation 9) (0.35 g, 0.64 mmol) and trans-1,4-diaminocyclohexane (0.6 g, 6.14 mmol) was added for 3 hours. Heated at 105 ° C. Silica gel dissolved in a slight dichloromethane and eluted with a gradient system that changed from dichloromethane: methanol: rich aqueous ammonia (volume ratio 80: 20: 1.2) to dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 88: 12: 2). Purification by column chromatography. After evaporation of the appropriate fractions the residue was triturated with diethyl ether, filtered and dried to give the title compound (0.32 g, 79%) as a white solid.
[570]
[571] Preparation Example 33
[572] N- (1-benzyl-4-piperidinyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbo Nil] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[573]
[574] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- A mixture of 2-furanyl} -9H-purine-2-carboxylate (Preparation 9) (1.0 g, 1.83 mmol) and 1-benzyl-4-piperidinylamine (2.4 mL, 11 mmol) was added for 4 hours. Heated at 105 ° C. The mixture was dissolved in some dichloromethane and purified by silica gel column chromatography, eluting with a gradient system changing from dichloromethane: methanol (volume ratio 98: 2) to dichloromethane: methanol (volume ratio 95: 5). After evaporation of the appropriate fractions, the residue was triturated with diethyl ether, filtered and dried to afford the title compound (1.0 g, 80%) as a white solid.
[575]
[576] Preparation Example 34
[577] N-[(3R) -1-benzylpyrrolidinyl] -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) Carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[578]
[579] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- The title compound was prepared in a similar manner to Preparation 33 using 2-furanyl} -9H-purine-2-carboxylate (Preparation Example 9) and (3R) -1-benzylpyrrolidinylamine as starting materials. The title compound was obtained as a white solid.
[580]
[581] Preparation 35
[582] N-[(3S) -1-benzylpyrrolidinyl] -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) Carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide
[583]
[584] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro- The title compound was prepared in a similar manner to Preparation 33 using 2-furanyl} -9H-purine-2-carboxylate (Preparation Example 9) and (3S) -1-benzylpyrrolidinylamine as starting materials. The title compound was obtained as a white solid.
[585]
[586] Preparation Example 36
[587] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N- (4-piperidinyl) -9H-purine-2-carboxamide
[588]
[589] N- (1-benzyl-4-piperidinyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5- in ethanol (10 mL) [(Ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 33) (1.03 g, 1.47 mmol), palladium hydroxide ( II) A solution of (0.9 g) and ammonium formate (0.46 g, 7.3 mmol) was heated at reflux for 3 h. The catalyst was filtered off with avocel and evaporated under reduced pressure to remove the solvent and changed from dichloromethane: methanol: rich aqueous ammonia (volume ratio 90: 10: 1) to dichloromethane: methanol: rich aqueous ammonia (volume ratio 80: 20: 2). The residue was purified by silica gel column chromatography eluting with a gradient system. After evaporation of the appropriate fractions the title compound (0.6 g, 67%) was obtained as a white solid.
[590]
[591] Preparation Example 37
[592] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N-[(3R) -pyrrolidinyl] -9H-purine-2-carboxamide
[593]
[594] N-[(3R) -1-benzylpyrrolidinyl] -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) The title compound was prepared in a similar manner to Preparation 36 using carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 34) as a starting material. Prepared. The title compound was obtained as a white solid.
[595]
[596] Preparation Example 38
[597] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N-[(3S) -pyrrolidinyl] -9H-purine-2-carboxamide
[598]
[599] N-[(3S) -1-benzylpyrrolidinyl] -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) The title compound was prepared in a similar manner to Preparation 36 using carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxamide (Preparation 35) as a starting material. Prepared. The title compound was obtained as a white solid.
[600]
[601] Preparation Example 39
[602] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 Furanyl) -9H-purine-2-carboxylic acid
[603]
[604] Methyl 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4- in methanol (2.3 mL) A solution of dihydroxytetrahydro-2-furanyl} -9H-purine-2-carboxylate (Preparation Example 9) and 10% (weight / weight) aqueous sodium hydroxide solution (1.3 ml, 3.2 mmol) was stirred for 14 hours at room temperature. Was stirred. The solution was adjusted to pH 4 by addition of 2N aqueous hydrochloric acid and filtered to collect the precipitated white solid. The solid was washed with water and dried under reduced pressure to give the title compound (0.21 g, 30%) as a white powder.
[605]
[606] Preparation Example 40
[607] (2S, 3S, 4R, 5R) -5- [6-[(2,2-diphenylethyl) amino] -2-({4-[(trifluoroacetyl) amino] -1-piperidinyl} Carbonyl) -9H-purin-9-yl] -N-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide
[608]
[609] 6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4- in dichloromethane (5 mL) Dihydroxytetrahydro-2-furanyl) -9H-purine-2-carboxylic acid (Preparation Example 39) (0.2 g, 0.38 mmol), 2,2,2-trifluoro-N- (4-piperidinyl A solution of acetamide (83 mg, 0.42 mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (81 mg, 0.42 mmol) was stirred at room temperature for 48 hours and then at reflux for 96 hours. Further heated. The solution was cooled to room temperature and removed by evaporation of the solvent under reduced pressure, changing from dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 95: 5: 1) to dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 80: 20: 1). The residue was purified by silica gel column chromatography eluting with the system. After evaporation of the appropriate fractions the title compound (43 mg, 18%) was obtained as a white solid.
[610]
[611] Preparation Example 41
[612] (2S, 3S, 4R, 5R) -5- {2-[(4-amino-1-piperidinyl) carbonyl] -6-[(2,2-diphenylethyl) amino] -9H-purine- 9-yl} -N-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide
[613]
[614] (2S, 3S, 4R, 5R) -5- [6-[(2,2-diphenylethyl) amino] -2-({4-[(trifluoroacetyl) amino]-in methanol (1 mL) 1-piperidinyl} carbonyl) -9H-purin-9-yl] -N-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide (Preparation 40) (40 mg, 0.056 mmol) Solution and concentrated aqueous ammonia solution (0.5 mL) were stirred at room temperature for 48 hours. The solvent was evaporated off under reduced pressure to give the title compound (35 mg) as a white solid.
[615]
[616] Preparation Example 42
[617] N-[(3R) -1-benzylpyrrolidinyl] -N '-[2- (diisopropylamino) ethyl] urea
[618]
[619] (3R) -1-benzylpyrrolidinylamine (0.5 g, 2.84 mmol) was added (3R) -1-benzylpyrrolidinylamine in 1,1,1-trichloroethane (2.5 mL) and isopropanol (2.5 mL). (0.5 g, 2.84 mmol) was added to a high solution of N- [2- (diisopropylamino) ethyl] -1H-imidazole-1-carboxamide (Preparation 19) and the reaction mixture was refluxed for 4 hours. Heated. The solution was cooled to room temperature and the solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography eluting with a gradient system changing from dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 95: 5: 0.5) to dichloromethane: methanol: concentrated aqueous ammonia (volume ratio 90: 10: 2). . After evaporation of the appropriate fractions the title compound (0.98 g) was obtained as a white solid.
[620]
[621] Preparation Example 43
[622] N-[(3S) -1-benzylpyrrolidinyl] -N '-[2- (diisopropylamino) ethyl] urea
[623]
[624] Start (3S) -1-benzylpyrrolidinylamine and N- [2- (diisopropylamino) ethyl] -1H-imidazol-1-carboxamide (Preparation 19) (40 mg, 0.17 mmol) Using the material, the title compound was prepared in the same manner as in Preparation 42. The title compound was obtained as a white solid.
[625]
[626] Preparation Example 44
[627] N- [2- (diisopropylamino) ethyl] -N '-[(3R) -pyrrolidinyl] urea
[628]
[629] N-[(3R) -1-benzylpyrrolidinyl] -N '-[2- (diisopropylamino) ethyl] urea (Preparation 42) (1.10 g, 3.16 mmol) in ethanol (10 mL), hydroxide A solution of palladium (II) (1.0 g) ammonium formate (1.0 g, 16 mmol) was heated under reflux for 2 hours. The catalyst was filtered off with avocel and the solvent was removed by evaporation under reduced pressure to give the title compound (0.6 g, 67%) as a white solid.
[630]
[631] Preparation Example 45
[632] N- [2- (diisopropylamino) ethyl] -N '-[(3S) -pyrrolidinyl] urea
[633]
[634] The title compound in the same manner as in Preparation 44 using N-[(3S) -1-benzylpyrrolidinyl] -N '-[2- (diisopropylamino) ethyl] urea (Preparation 43) as starting material Was prepared. The title compound was obtained as a white solid.
[635]
[636] Preparation Example 46
[637] (2R, 3R, 4S, 5S) -2- (2-Amino-6-chloro-9H-purin-9-yl) -4- (benzoyloxy) -5-[(ethylamino) carbonyl] tetrahydro- 3-furanyl benzoate
[638]
[639] A suspension of 2-amino-6-chloropurine (4.60 g, 27.13 mmol) in 1,1,1-trichloroethane (230 mL) was charged with N, O-bis (trimethylsilyl) acetamide (20 mL, 81.4 mmol). And reacted with The mixture was heated at reflux for 6 h. The solution was cooled to rt and the solvent was removed under reduced pressure. The residue was taken up in (2S, 3S, 4R, 5R)-and (2S, 3S, 4R, 5S) -5- (in anhydrous toluene (230 mL) and trimethylsilyl trifluoromethanesulfonate (20 mL, 108.5 mmol). It was reacted with a solution of acetyloxy) -4- (benzoyloxy) -2-[(ethylamino) carbonyl] tetrahydro-3-furanylbenzoate (Preparation 14) (14.39 g, 32.6 mmol). The resulting solution was then heated at 90 ° C. for 90 minutes under a nitrogen atmosphere. The mixture was cooled to room temperature, diluted with ethyl acetate (250 mL), washed with saturated aqueous sodium hydrogen carbonate solution (350 mL), and then brine (350 mL). The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane: methanol (volume ratio 98: 2) to afford the title compound (8.1 g) as a foam.
[640]
[641] Preparation 47
[642] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-chloro-2-iodo-9H-purin-9-yl) -5-[(ethylamino) carbonyl] tetrahydro 3-furanyl benzoate
[643]
[644] n-butyl nitrite (4.65 mL, 39.7 mmol) was dissolved in THF (100 mL) (2R, 3R, 4S, 5S) -2- (2-amino-6-chloro-9H-purin-9-yl) -4 -(Benzoyloxy) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate (Preparation 46) (8.10 g, 14.7 mmol), iodine (3.73 g, 14.7 mmol), copper iodide ( I) (6.16 g, 32.3 mmol) and diiodomethane (12.55 mL, 155.8 mmol) were added to the suspension and the mixture was heated at reflux for 2.5 h. The solution was cooled to rt and the solvent was removed under reduced pressure. The residue was partitioned in aqueous sodium metabisulfite solution (5% weight / volume, 100 mL) and dichloromethane (100 mL). The organic layer was separated, filtered through avocel, dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure. Purification of the residue by silica gel column chromatography eluting with dichloromethane: methanol (volume ratio 99: 1) gave the title compound (7.55 g, 78%) as a yellow foam.
[645]
[646] Preparation Example 48
[647] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-{[2,2-bis (3-methylphenyl) ethyl] amino} -2-iodo-9H-purine-9- Yl) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate
[648]
[649] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-chloro-2-iodo-9H-purin-9-yl) -5-[(ethylamino in isopropanol (20 mL) ) A solution of carbonyl] tetrahydro-3-furanyl benzoate (Preparation 47) (0.6 g, 0.91 mmol) and 2,2-bis (3-methylphenyl) ethylamine (0.3 g, 1.36 mmol) at room temperature Stir for 48 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane: methanol (volume ratio 99: 1) to afford the title compound (0.67 g, 87%) as a beige foam.
[650]
[651] Preparation 49
[652] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-{[2,2-bis (3-chlorophenyl) ethyl] amino} -2-iodo-9H-purine-9 -Yl) -5-[(ethylamino) carbonyl] tetrahydro-3-furanyl benzoate
[653]
[654] (2R, 3R, 4S, 5S) -4- (benzoyloxy) -2- (6-chloro-2-iodo-9H-purin-9-yl) -5-[(ethylamino) carbonyl] tetrahydro The title compound was prepared in the same manner as in Preparation 48, using 3-furanyl benzoate (Preparation 47) and 2,2-bis (3-chlorophenyl) ethylamine as starting materials. The title compound was obtained as a yellow foam.
[655]
[656] Preparation 50
[657] Benzyl 2-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] ethyl carbamate
[658]
[659] Benzyl 2-aminoethylcarbamate hydrochloride (4.33 g, 18.8 mmol) in dichloromethane (100 mL), N- [2- (diisopropylamino) ethyl] -1 H-imidazole-1-carboxamide (prepared) Example 19) (3.73 g, 15.64 mmol) and a solution of triethylamine (2.62 mL, 18.8 mmol) were heated at reflux for 14 h. The solution was cooled to room temperature and washed with water (20 mL). The aqueous layer was separated and further extracted with dichloromethane (20 mL). The combined organic layers were dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure to give the title compound (6.25 g) as a yellow oil.
[660]
[661] Preparation Example 51
[662] Benzyl 2-[({[2- (1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl carbamate
[663]
[664] Preparative Example 50 using benzyl 2-aminoethylcarbamate hydrochloride and N- [2- (1-piperidinyl) ethyl] -1H-imidazole-1-carboxamide (Preparation 18) as starting material The title compound was prepared in a similar manner. The title compound was obtained as a yellow oil.
[665]
[666] Preparation Example 52
[667] N- (2-aminoethyl) -N '-[2- (diisopropylamino) ethyl] urea
[668]
[669] A solution of benzyl 2-[({[2- (diisopropylamino) ethyl] amino} carbonyl) amino] ethyl carbamate (Preparation 50) (6.25 g, 14.45 mmol) in ethanol (100 mL) was 414 kPa. Palladium (II) hydroxide (250 mg) was hydrogenated at room temperature for 4 hours. The catalyst was filtered off with Avocel and the solvent was evaporated under reduced pressure. Purify the residue by silica gel column chromatography, eluting with a gradient system that changes from dichloromethane: methanol: rich aqueous ammonia (volume ratio 90: 10: 1) to dichloromethane: methanol: condensed aqueous ammonia (volume ratio 90: 10: 2). The title compound (3.6 g) was obtained as a yellow oil.
[670]
[671] Preparation Example 53
[672] N- (2-aminoethyl) -N '-[2- (1-piperidinyl) ethyl] urea
[673]
[674] Benzyl 2-[({[2- (1-piperidinyl) ethyl] amino} carbonyl) amino] ethyl carbamate (Preparation 51) was used as starting material to prepare the title compound in a similar manner as in Preparation 52. It was. The title compound was obtained as a yellow oil.
[675]
[676] Preparation Example 54
[677] Benzyl 4-{[(1H-imidazol-1-ylcarbonyl) amino] methyl} benzoate
[678]
[679] Benzyl 4- (aminomethyl) benzoate hydrochloride (1.0 g, 36 mmol) was dissolved in 10% (w / w) aqueous sodium hydroxide solution (20 mL) and the solution extracted with dichloromethane (30 mL). The organic phase was separated, dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure to give the free base of the amine as a thick oil. It was dissolved in dichloromethane (20 mL) and the solution was added dropwise to a solution of N, N'-carbonyldiimidazole (1.62 g, 10 mmol) in dichloromethane (20 mL). After stirring for 1 hour at room temperature the reaction mixture was diluted with diethyl ether (100 mL) and washed three times with water (40 mL) and brine (40 mL). The solution was dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure to afford the title compound (0.97 g, 81%) as a white solid.
[680]
[681] Preparation Example 55
[682] Benzyl 4-[({[(2-{[(6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl ] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purin-2-yl) carbonyl] amino} ethyl) amino] carbonyl} amino) methyl] benzoate
[683]
[684] N- (2-aminoethyl) -6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3, 4-dihydroxytetrahydro-2-furanyl} -9H-purin-2-carboxamide (Preparation 10) and benzyl 4-{[(1H-imidazol-1-ylcarbonyl) amino] methyl} The title compound was prepared in a similar manner to Example 1 using benzoate (Preparation 54) as the starting material. The title compound was obtained as a white solid.
[685]
[686] Preparation Example 56
[687] N- [2- (dibutylamino) ethyl] -1 H-imidazole-1-carboxamide
[688]
[689] The title compound was prepared in a similar manner to Preparation Example 19 using N ', N'-dibutyl-1,2-ethanediamine and N, N'-carbonyldiimidazole as starting materials. The title compound was obtained as a white solid.
[690]
[691] Preparation Example 57
[692] N- {2- [benzyl (isopropyl) amino] ethyl) -1H-imidazole-1-carboxamide
[693]
[694] The title compound was prepared in a similar manner to Preparation Example 19 using N'-benzyl-N'-isopropyl-1,2-ethanediamine and N, N'-carbonyldiimidazole as starting materials. The title compound was obtained as a white solid.
[695]
[696] Preparation 58
[697] N- (1-benzyl-4-piperidinyl) -1H-imidazole-1-carboxamide
[698]
[699] The title compound was prepared in a similar manner to Preparation Example 19 using 1-benzyl-4-piperidinylamine and N, N'-carbonyldiimidazole as starting materials. The title compound was obtained as a white solid.
[700]
[701] Preparation Example 59
[702] N-[(1-benzyl-4-piperidinyl) methyl] -1 H-imidazole-1-carboxamide
[703]
[704] The title compound was prepared in a similar manner to Preparation Example 19 using (1-benzyl-4-piperidinyl) methylamine and N, N'-carbonyldiimidazole as starting materials. The title compound was obtained as a white solid.
[705]
[706] Preparation Example 60
[707] N- {4-[(diethylamino) methyl] benzyl} -1H-imidazole-1-carboxamide
[708]
[709] The title compound was prepared in a similar manner to Preparation Example 19 using N- [4- (aminomethyl) benzyl] -N, N-diethylamine and N, N'-carbonyldiimidazole as starting materials. The title compound was obtained as a white solid.
[710]
[711] Preparation Example 61
[712] N- [2- (3,4-dihydro-2 (1H) -isoquinolinyl) ethyl] -1H-imidazole-1-carboxamide
[713]
[714] The title compound was prepared in a similar manner to Preparation Example 19 using 2- (3,4-dihydro-2 (1H) -isoquinolinyl) ethylamine and N, N'-carbonyldiimidazole as starting materials. . The title compound was obtained as a white solid.
[715]
[716] Preparation Example 62
[717] Ethyl 6-[(2,2-diphenylethyl) amino] -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-2-carboxylate
[718]
[719] To a suspension of palladium (II) acetate (1.50 g, 0.00668 mole) in pure ethanol (1000 mL) was added 1,1'-bis (diphenylphosphino) ferrocene (7.00 g, 0.0126 mole) and the resulting suspension was nitrogen Stirring under air for 18 hours yields a catalyst mixture. 2-chloro-N- (2,2-diphenylethyl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-amine (WO / 0023457) ( Preparation Example 2) To a mixture of (700 g, 1.61 mole) and pure ethanol (4500 mL) was added anhydrous sodium carbonate (94 g, 0.887 mole) and the catalyst mixture prepared above in an autoclave. The autoclave was spun twice with carbon monoxide gas and then pressurized to 2000 kPa using carbon monoxide gas. The mixture was then heated with stirring for 10 minutes at < RTI ID = 0.0 > 103-107 C, < / RTI > Heated at 103-107 [deg.] C. for additional 14 hours with continued stirring. The mixture was cooled to 60 ° C. and then filtered through a layer of warm Celite®. As soon as the resulting filtrate was cooled to ambient temperature it began to crystallize and after stirring for 7 hours at the same temperature the resulting suspension was filtered. The filter cake was washed with pure cold ethanol (500 mL) and the solid was dried under vacuum at 55 ° C. for 24 hours to afford the title compound as a cream solid (575 g) with a melting point of 138-140 ° C.
[720]
[721] Preparation Example 63
[722] Ethyl 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate
[723]
[724] Ethyl 6-[(2,2-diphenylethyl) amino] -9- (tetrahydro-2H-pyran-2-yl) -9H-purin-2-carboxylate in pure ethanol (150 mL) (Preparation 62 Trifluoroacetic acid (73.5 g, 0.645 mole) was added to a solution of (250 g, 0.530 mole) under a nitrogen atmosphere and the resulting mixture was heated at 50 ° C. for 20 h. The mixture was cooled and the solid collected by filtration. The filter cake was washed with pure ethanol (350 mL) and dried at 50 ° C. in vacuo to yield the title compound as a cream color (206.5 g) with a melting point above 200 ° C.
[725]
[726] Preparation Example 64
[727] Ethyl 9-{(2R, 3R, 4R, 5R) -3,4-bis (acetyloxy) -5-[(acetyloxy) methyl] tetrahydro-2-furanyl} -6-[(2,2 -Diphenylethyl) amino] -9H-purine-2-carboxylate
[728]
[729] Of ethyl 6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylate (Preparation 63) (40.0 g, 0.103 mole) in anhydrous 1,2-dimethoxyethane (240 mL) To the suspension was added 4-methylmorpholine (11.5 g, 12.5 mL, 0.114 mole) under a nitrogen atmosphere and the resulting mixture was heated to 45 ° C. with stirring. Trimethylsilyl trifluoromethanesulfonate (27.5 g, 22.4 mL, 0.124 mole) was then added to the mixture over 10 minutes. The resulting orange solution was then heated to 55 ° C. and 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose in 1,2-dimethoxyethane (100 mL + 20 mL for washing) A solution of 36.1 g, 0.113 mole) was added over 10 minutes and then the reaction solution was stirred at 57-60 ° C. for 2 hours and then the mixture was cooled to ambient temperature. The reaction mixture was then added carefully to a mixture of saturated aqueous sodium bicarbonate solution (400 mL) and ethyl acetate (400 mL) with vigorous stirring. The layers were separated and the aqueous phase was extracted with ethyl acetate (400 mL). The combined organic phases were dried over anhydrous magnesium sulphate and concentrated in vacuo to afford the crude product (74.9 g) as an orange foam which can be used as such in the next step. The crude product was purified by silica gel column chromatography, eluting with a gradient system changing from 10% (volume / volume) diethylether in dichloromethane to 25% (volume / volume) diethylether in dichloromethane to give the title as a colorless foam. Compounds can be obtained.
[730]
[731] Preparation 65
[732] Ethyl 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[(2,2-diphenylethyl) Amino] -9H-purine-2-carboxylate
[733]
[734] Crude ethyl 9-{(2R, 3R, 4R, 5R) -3,4-bis (acetyloxy) -5-[(acetyloxy) methyl] tetrahydro-2-furanyl} in pure warm ethanol (330 mL) Sodium ethoxide (1.2 g, 0.018 mole) in a solution of -6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate (Preparation 64) (74.9 g, about 0.103 mole) Was added in portions over 23 hours. The resulting mixture was further stirred for 3 hours and then glacial acetic acid (1.5 mL) was added. The mixture was concentrated in vacuo to afford the crude product as a light brown foam (63.7 g), which was used as such in the next step. Silica gel column chromatography eluting with a gradient system that changes from 5% (volume / volume) isopropanol in dichloromethane to 7.5% (volume / volume) isopropanol in dichloromethane and then to 10% (volume / volume) isopropanol in dichloromethane. The crude product can be purified by chromatography and crystallized with tert-butyl methyl ether to afford the title compound as colorless crystalline having a melting point of 118 to 120 ° C.
[735]
[736] Preparation 66
[737] Ethyl 9-[(3aR, 4R, 6R, 6aR) -6- (hydroxymethyl) -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-yl]- 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate
[738]
[739] Crude ethyl 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[(in anhydrous acetone (314 mL) To a solution of 2,2-diphenylethyl) amino] -9H-purine-2-carboxylate (Preparation 65) (62.7 g, about 0.103 mole) was added concentrated sulfuric acid (5.3 ml, 0.103 mole) under a nitrogen atmosphere. The resulting mixture was stirred at ambient temperature for 2.5 hours. Then 2,2-dimethoxypropane (21.5 g, 25.4 mL, 0.207 mole) was added and stirring continued for an additional 2.5 hours. The reaction mixture was then added to saturated aqueous sodium bicarbonate solution (300 mL) and the resulting mixture was stirred at ambient temperature for 0.2 h. The mixture was concentrated in vacuo and the aqueous residue was extracted with ethyl acetate (400 mL, then 200 mL). The organic phases were combined, washed with saturated brine (300 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo to give a yellow foam (58.2 g). A solution of this material in tert-butyl methylether (250 mL) was stirred at ambient temperature under a nitrogen atmosphere to give a suspension which was then cooled in ice for 1 hour and then the solid was collected by filtration. The filter cake was washed with cold tert-butyl methyl ether (50 mL) and the product dried under vacuum to afford the title compound as a colorless solid (12.7 g). Purification of the mother liquor by silica gel (400 g) flash chromatography eluting with 75% (volume / volume) ethyl acetate in heptane yielded a slightly impure product (32.9 g) as a foam and with tert-butyl methyl ether (150 mL). Crystallization further gave the title compound (8.3 g). Re-concentrate the mother liquor under vacuum to give foam (23.2 g) and elute using a gradient system that changes from 50% (volume / volume) ethylacetate in toluene to 90% (volume / volume) ethylacetate in toluene. Purification by chromatography gave two fractions (9.7 g and 11.8 g), and crystallized separately with tert-butyl methyl ether (100 mL and 120 mL, respectively) to add the title compound (6.6 g and 8.8 g, respectively). Obtained. Thus a total of 36.4 g of the title compound were obtained and isolated as a colorless crystalline solid with a melting point of 126 to 128 ° C.
[740]
[741] Preparation Example 67
[742] (3aS, 4S, 6R, 6aR) -6- [6-[(2,2-diphenylethyl) amino] -2- (ethoxycarbonyl) -9H-purin-9-yl] -2,2- Dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-carboxylic acid
[743]
[744] Ethyl 9-[(3aR, 4R, 6R, 6aR) -6- (hydroxymethyl) -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4- in acetonitrile 2,2,6,6-tetra in a solution of Japanese] -6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate (Preparation 66) (15.4 g, 0.0276 mole) Methylpiperidinyl-1-oxy free radicals (0.30 g, 0.0019 mole) and 0.67 M aqueous sodium dihydrogen phosphate solution (120 mL) were added under nitrogen atmosphere. The resulting mixture was heated to 45 ° C. with stirring. A solution of sodium chlorite (6.5 g, 0.072 mole) in water (75 mL) and a commercial solution of sodium hypochlorite (0.32 mL, 0.000551 mole) containing 12% (weight / volume) chlorine in water (38 mL) Were added simultaneously simultaneously to the stirred mixture over 1 hour. The resulting mixture was then stirred at 45-50 ° C. for 10 hours and at ambient temperature for 18 hours. The reaction mixture was then added with stirring to a solution of sodium sulfite (18 g, 0.143 mole) in water (300 mL). After stirring for 5 minutes, the pH was adjusted to 3.7 by addition of 2M aqueous hydrochloric acid and the mixture was extracted with ethyl acetate (200 mL, then 100 mL). The organic phases were combined, dried over anhydrous magnesium sulfate and concentrated in vacuo to afford the title compound (15.1 g) as a colorless foam which was used as such in the next step. If desired, the crude product can be purified by standard methods, for example silica gel flash chromatography.
[745]
[746] Preparation Example 68
[747] (3aS, 4S, 6R, 6aR) -6- [6-[(2,2-diphenylethyl) amino] -2- (ethoxycarbonyl) -9H-purin-9-yl] -2,2- Dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-carboxylic acid
[748]
[749] Ethyl 9-[(3aR, 4R, 6R, 6aR) -6- (hydroxymethyl) -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] di in dichloromethane (75 mL) 2,2,6 in a solution of oxol-4-yl] -6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylate (Preparation 66) (5.0 g, 0.0089 mole) , 6-tetramethylpiperidinyl-1-oxy free radicals (0.020 g, 0.000128 mole), tetrabutylammonium bromide (0.22 g, 0.000682 mole) and saturated aqueous sodium bicarbonate solution (25 mL) were added. To the rapidly stirred mixture was then added 0.531 M aqueous sodium hypochlorite solution (33 ml, 0.0175 mole) at ambient temperature over 15 minutes and stirring continued for an additional 1.5 hours. To the resulting mixture was added an aqueous sodium sulfite solution (50 mL of (10% (weight / volume) solution)) and stirring continued for 10 minutes, after which the slightly cloudy organic phase was separated and then concentrated in vacuo to give a yellow foam. This material was partitioned between ethyl acetate (50 mL) and 2M aqueous hydrochloric acid solution (25 mL), then the organic phase was washed with water and concentrated in vacuo The residue was redissolved in ethyl acetate (50 mL) and vacuumed Re-concentration under afforded the title compound (5.23 g) as a pale yellow foam which was used as such in the next step, if necessary, the crude compound can be purified by standard methods, for example silica gel flash chromatography.
[750]
[751] Preparation Example 69
[752] Ethyl 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4- Japanese} -6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate
[753]
[754] (3aS, 4S, 6R, 6aR) -6- [6-[(2,2-diphenylethyl) amino] -2- (ethoxycarbonyl) -9H-purine- in anhydrous tetrahydrofuran (100 mL) 9, yl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-carboxylic acid (Preparations 67 and 68) (20.0 g, 0.0349 mole) 1'-carbonyldiimidazole (6.80 g, 0.0418 mole) was added under a nitrogen atmosphere and the resulting mixture was stirred at ambient temperature for 1.5 hours. To the solution was then added a solution of ethylamine in tetrahydrofuran (24.4 mL of 2M solution, 0.0488 mole) while cooling at 15 ° C. and the resulting mixture was stirred at ambient temperature for 2 hours. The mixture was further added a solution of ethylamine in tetrahydrofuran (3.5 mL of 2M solution, 0.0007 mole) and further stirred for 2 hours followed by the addition of deionized water (10 mL). The resulting mixture was concentrated in vacuo and the residue was partitioned between ethyl acetate (200 mL) and 0.5M citric acid aqueous solution (200 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined and washed successively with deionized water (200 mL), saturated aqueous sodium bicarbonate solution (200 mL) and saturated brine (200 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo to afford a crude product as a creamy foam (20.22 g). ) Was obtained. The crude product was purified by silica gel (700 g) flash chromatography, changing from 65% (volume / volume) ethylacetate in heptane to 80% (volume / volume) ethylacetate in heptane and then changing to ethylacetate. The title compound (16.55 g) was obtained as a colorless foam.
[755]
[756] Preparation 70
[757] 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-yl } -6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylic acid
[758]
[759] Ethyl 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3 in methanol (164 mL) 1M sodium hydroxide in a solution of [dioxol-4-yl} -6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylate (Preparation 69) (16.47 g, 0.0274 mole) An aqueous solution (30.2 mL, 0.0302 mole) was added and the resulting mixture was stirred for 1.5 h at ambient temperature under a nitrogen atmosphere. The reaction mixture was then concentrated in vacuo and dichloromethane (160 mL) and deionized water (160 mL) were added to the residue. 2M aqueous hydrochloric acid was added with stirring to adjust the pH of the mixture to 4. The organic phase was separated and the aqueous layer extracted with dichloromethane (75 mL). The organic phases were then combined, dried over anhydrous magnesium sulfate and concentrated in vacuo to yield the title compound (15.5 g) as a cream colored foam which was used as such in the next step. If desired, the crude compound can be purified by standard methods, for example silica gel flash chromatography.
[760]
[761] Preparation Example 71
[762] 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-yl } -6-[(2,2-diphenylethyl) amino] -N- {2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide
[763]
[764] 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3 in dichloromethane (75 mL) 1,1 'in a solution of [dioxol-4-yl} -6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylic acid (Preparation 70) (14.98 g, 0.0262 mole) Carbonyldiimidazole (4.7 g, 0.029 mole) was added under a nitrogen atmosphere and the resulting mixture was stirred at ambient temperature for 1.5 hours to give an induced acyl imidazolide solution. N- (2-aminoethyl) -N '-[1- (2-pyridinyl) -4-piperidinyl] ureadihydrochloride (Preparation 73) in dichloromethane (75 mL) (10.1 g, 0.0301 mole) Triethylamine (5.6 g, 7.7 mL, 0.055 mole) was added to a solution of) under a nitrogen atmosphere and the resulting suspension was embossed to 15 ° C. To the suspension was then added the acyl imidazolide solution prepared above and the resulting mixture was stirred at ambient temperature for 2 hours and then deionized water (5 mL) was added. The mixture was washed with 0.5M aqueous citric acid solution (150 mL) saturated with sodium chloride. The layers were separated and the aqueous phase extracted with dichloromethane (75 mL). The organic phases were combined and washed with saturated aqueous sodium bicarbonate solution. The phases were separated and the aqueous layer was extracted with dichloromethane (75 mL), then the organic phases were combined, dried over anhydrous magnesium sulfate and concentrated in vacuo to yield the title compound (21.28 g) as a light blue foam which was used as is in the next step. It was. The crude product can be purified by silica gel flash chromatography eluting with a standard method, for example a system comprising dichloromethane: methanol: concent aqueous ammonia (volume ratio 95: 5: 0.5) to afford the pure title compound.
[765]
[766] Preparation Example 72
[767] t-butyl 2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl carbamate
[768]
[769] 1- (2-pyridinyl) -4-piperidinylamine dichloride (European EP-A-0021973) (20.82 g, 0.0832 mole) and 1,1'-carbonyldiimine in acetonitrile (140 mL) To an ice cold solution of dozol (14.85 g, 0.915 mole) was added N, N-diisopropylethylamine (22.0 g, 29.7 mL, 0.170 mole) over 20 minutes under a nitrogen atmosphere. The resulting light brown solution was stirred at ambient temperature for 20 minutes and a solution of tert-butyl N- (2-aminoethyl) carbamate (14.0 g, 0.0874 mole) in acetonitrile (10 mL + 5 mL for washing) was added. Add over 5 minutes. The resulting mixture was then heated to reflux for 2.5 h. After cooling to ambient temperature the reaction mixture was concentrated in vacuo and the residue dissolved in ethyl acetate (150 mL). The solution was washed successively with saturated aqueous sodium bicarbonate solution (70 mL) and deionized water (20 mL). The aqueous phase was extracted twice with ethyl acetate (100 mL) and the combined organic phases were washed with water. The organic phase was dried over anhydrous magnesium sulfate and the solution was concentrated in vacuo to a volume of about 200 mL. The resulting solution was then distilled under atmospheric pressure until the volume reached about 75 mL. Crystallization occurred while cooling the solution to ambient temperature. The resulting thick slurry was diluted with ethyl acetate (60 mL) and cooled on ice. The solid was collected by filtration and the filter foil was washed twice with cold ethyl acetate (30 mL). The resulting solid was dried under vacuum at 50 ° C. for 20 minutes to give crude product (24.0 g) and recrystallized from ethyl acetate (270 mL) to give the title compound (20.7 g) as a colorless solid.
[770]
[771] Preparation Example 73
[772] N- (2-aminoethyl) -N '-[1- (2-pyridinyl) -4-piperidinyl] urea dihydrochloride
[773]
[774] T-butyl 2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl carbamate (Preparation 72) (20.6 g, in ethyl acetate (115 mL), To a solution of 0.0567 mole) a saturated solution of hydrogen chloride in ethyl acetate (ml115) was added under a nitrogen atmosphere and the resulting thick slurry was stirred at ambient temperature for 2 hours. The solid was collected by filtration and the filter foil was washed twice with ethyl acetate (50 mL) and dried at 50 ° C. in vacuo to yield the title compound (21.0 g) as a hygroscopic colorless solid with a melting point of 112 to 120 ° C.
[775] Positive Pressure Chemical Ionization (LRMS): m / z [M−H ⁺ ] 264.
[776]
[777] Preparation Example 74
[778] N- (2-aminoethyl) -N '-[1- (2-pyridinyl) -4-piperidinyl] urea
[779]
[780] 1,1 'in a suspension of 1- (2-pyridinyl) -4-piperidinylamine dihydrochloride (European EP-A-0021973) (1.0 g, 0.0040 mole) in ethyl acetate (10 mL). Carbonyldiimidazole (0.713 g, 0.0044 mole) was added under a nitrogen atmosphere and the resulting mixture was stirred at ambient temperature for 1 hour. Then triethylamine (0.40 g, 0.5 mL, 0.004 mole) was then added and further stirred for 2 hours followed by N, N'-carbonyldiimidazole (0.145 g, 0.0009 mole). The reaction mixture was further stirred for 2 hours and then 1,2-diaminoethane (2.4 g, 2.7 mL) in ethyl acetate (3 mL) with additional ethyl acetate (17 mL) used to thoroughly clean the apparatus. 0,04 mole) was added over 15 minutes. The resulting mixture was stirred at ambient temperature for 18 hours and washed with saturated aqueous sodium bicarbonate solution. The layers were then separated and the aqueous phase was extracted twice with ethyl acetate (20 mL). The organic layers were then combined, dried over anhydrous magnesium sulfate and concentrated in vacuo to afford the crude product (0.83 g). Free base obtained using the title compound (N- (2-aminoethyl) -N '-[1- (2-pyridinyl) -4-piperidinyl] urea dihydrochloride (Preparation 73) as starting material. The crude product was examined by high performance liquid chromatography-mass spectroscopy and 1 H NMR as compared to a pure sample of), and the title compound was present as the main component with a small amount of impurities.
[781]
[782] Pharmacological data
[783] The compounds of Examples 1 to 35 were tested for biological activity by the method described in page 62 of the specification and all compounds were found to have an IC ₅₀ of less than 100 nM.

权利要求:
Claims (78)
[1" claim-type="Currently amended] A compound of formula (I), or a pharmaceutically acceptable salt or solvent compound thereof:
Formula I

Where
R ¹ is H, C ₁ -C ₆ alkyl or fluorenyl, wherein C ₁ -C ₆ alkyl is phenyl, optionally substituted with C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy, halo or cyano And it is unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of naphthyl;
(A) R ² is H or C ₁ -C ₆ alkyl; R ¹⁵ is H or C ₁ -C ₆ alkyl; X is (i) unbranched C ₂ -C ₃ alkylene optionally substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl or (ii) the formula-(CH ₂ ) _n -W- ( CH ₂ ) _p -is a group; W is C ₅ -C ₇ cycloalkylene optionally substituted with C ₁ -C ₆ alkyl; n is 0 or 1; p is 0 or 1;
(B) R ¹⁵ is H or C ₁ -C ₆ alkyl; R ² and X together with the nitrogen atom to which they are attached, azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, unsubstituted or substituted with C ₁ -C ₆ alkyl, respectively, Forms piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; or
(C) R ² is H or C ₁ -C ₆ alkyl; R ¹⁵ and X together with the nitrogen atom to which they are attached, azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, unsubstituted or substituted with C ₁ -C ₆ alkyl, respectively, Forms piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl;
R ³ and R ⁴ together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each on a ring nitrogen or carbon atom Unsubstituted or substituted with -NR ⁶ R ⁷ on a ring carbon atom which is unsubstituted or substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl and which is not adjacent to the ring nitrogen atom; or
R ³ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl; R ⁴ is (a) azetidin-3-yl, pyrrolidin-3- unsubstituted or substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl or het, respectively. 1, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, (b)-(C ₂ -C ₆ alkylene)- R ⁸ , (c)-(C ₁ -C ₆ alkylene) -R ¹³ or (d) C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl;
R ⁵ is CH ₂ OH or CONR ¹⁴ R ¹⁴ ;
R ⁶ and R ⁷ are independently of each other H or C ₁ -C ₆ alkyl; Or together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl or piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl;
R ⁸ is (i) C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₁ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring carbon atom Ring nitrogen atoms, each substituted or unsubstituted with (C ₁ -C ₆ ) -alkyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ⁹ or C ₂ -C ₅ alkanoyl and a fluoro-on ring carbon atoms that are not adjacent - (C ₁ -C ₆₎ - alkoxy, halo, -OR ^{9, _{cyano, -S (O) m R 10}} , -NR 9 R 9, -SO 2 NR 9 Azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4, unsubstituted or substituted with R ⁹ , -NR ⁹ COR ¹⁰ or -NR ⁹ SO ₂ R ¹⁰ . -Yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, wherein said piperazin-1-yl and homopiperazin- 1-yl is C ₁ -C ₆ alkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₂ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring nitrogen atom which is not bound to a C ₂ -C ₆ alkylene group (C ₂ -C ₆ ) -alkyl, flu Oro - (C ₁ -C ₆₎ - alkyl, C ₂ -C ₅ alkanoyl, -COOR ^10, C ₃ -C _{8 ^{cycloalkyl, -SO 2 R 10, -SO 2}} NR 9 R 9 or -CONR ⁹ R Substituted or unsubstituted with ⁹ ; Or (ii) NR ¹¹ R ¹² ;
R ⁹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
R ¹⁰ is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
R ¹¹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl;
R ¹² is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ¹⁰ , C _2- C ₅ alkanoyl or —SO ₂ NR ⁹ R ⁹ ;
R ¹³ is (a) C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy,-(C ₁ -C ₃ alkylene)-(C ₁ -C ₆ alkoxy), halo, cyano,-(C _1- C ₃ alkylene) -CN, -CO ₂ H,-(C ₁ -C ₃ alkylene) -CO ₂ H, -CO ₂ (C ₁ -C ₆ alkyl),-(C ₁ -C ₃ alkylene) -CO ₂ (C ₁ -C ₆ alkyl),-(C ₁ -C ₃ alkylene) -NR ¹⁴ R ¹⁴ , -CONR ¹⁴ R ¹⁴ or-(C ₁ -C ₃ alkylene) -CONR ¹⁴ R ¹⁴ Phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each substituted or unsubstituted; Or (b) azetidin-2-yl, azetidin-3-yl, pyrrolidin-, each optionally substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl or het. 2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-2-yl, homopiperidin- 3-yl or homopiperidin-4-yl;
R ¹⁴ is H, or C ₁ -C ₆ alkyl optionally substituted with cyclopropyl;
m is 0, 1 or 2;
Y is CO, CS, SO ₂ or C = N (CN);
“Het” as used in the definitions of R ⁴ and R ¹³ is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₆ alkoxy, C ₃ -C ₈ cycloalkoxy, hydroxy, oxo or halo Or C-bonded 4 to 6 membered ring heterocycle having 1 to 4 ring nitrogen heteroatoms, substituted or unsubstituted with 1 or 2 nitrogen ring heteroatoms, and 1 oxygen or 1 sulfur ring heteroatom. to be.
[2" claim-type="Currently amended] The method of claim 1,
R ¹ is C ₁ -C ₆ alkyl or halo-substituted or unsubstituted, or substituted with non-substituted with one or two phenyl substituents C ₁ -C ₆ alkyl compound.
[3" claim-type="Currently amended] The method of claim 2,
R ¹ is diphenylethyl, bis (3-methylphenyl) ethyl or bis (3-chlorophenyl) ethyl.
[4" claim-type="Currently amended] The method of claim 3, wherein
R ¹ is 2,2-diphenylethyl, 2,2-bis (3-methylphenyl) ethyl or 2,2-bis (3-chlorophenyl) ethyl.
[5" claim-type="Currently amended] The method of claim 4, wherein
R ¹ is 2,2-diphenylethyl.
[6" claim-type="Currently amended] The method according to any one of claims 1 to 5,
R ² is H.
[7" claim-type="Currently amended] The method according to any one of claims 1 to 6,
R ¹⁵ is H.
[8" claim-type="Currently amended] The method according to any one of claims 1 to 7,
X is 1,2-ethylene or 1,3-propylene.
[9" claim-type="Currently amended] The method of claim 8,
X is 1,2-ethylene.
[10" claim-type="Currently amended] The method according to any one of claims 1 to 5,
R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or a group of the formula-(CH ₂ ) _n -W- (CH ₂ ) _p- , W is C ₅ -C ₇ cycloalkylene, n is 0 or 1 and p is 0 or 1;
[11" claim-type="Currently amended] The method of claim 10,
R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or a group of the formula-(CH ₂ ) _n -W- (CH ₂ ) _p- , W is C ₅ -C ₇ cycloalkylene, n is 0 , p is 0.
[12" claim-type="Currently amended] The method of claim 11,
R ² is H; R ¹⁵ is H; X is 1,2-ethylene, 1,3-propylene or 1,4-cyclohexylene.
[13" claim-type="Currently amended] The method of claim 12,
R ² is H; R ¹⁵ is H; X is 1,2-ethylene.
[14" claim-type="Currently amended] The method according to any one of claims 1 to 5,
R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form a 3-pyrrolidinyl, or 3- or 4-piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl.
[15" claim-type="Currently amended] The method of claim 14,
R ¹⁵ is H; R ² and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl or 4-piperidinyl.
[16" claim-type="Currently amended] The method according to any one of claims 1 to 5,
R ² is H; Or R ¹⁵ and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl, or 3- or 4-piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl.
[17" claim-type="Currently amended] The method of claim 16,
R ² is H; R ¹⁵ and X together with the nitrogen atom to which they are attached form 3-pyrrolidinyl or 4-piperidinyl.
[18" claim-type="Currently amended] The method according to any one of claims 1 to 17,
R ³ is H. A compound.
[19" claim-type="Currently amended] The method according to any one of claims 1 to 18,
R ⁴ is piperidin-3-yl or piperidin-4-yl, optionally substituted with benzyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, wherein said pyridine- 2-yl, pyridin-3-yl and pyridin-4-yl are C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₆ alkoxy, C ₃ -C ₈ cycloalkoxy, hydroxy, Compounds substituted or unsubstituted with oxo or halo.
[20" claim-type="Currently amended] The method of claim 19,
R ⁴ is piperidin-3-yl or piperidin-4-yl, each substituted with benzyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl.
[21" claim-type="Currently amended] The method of claim 20,
R ⁴ is piperidin-4-yl substituted with pyridin-2-yl.
[22" claim-type="Currently amended] The method of claim 21,
R ⁴ is 1- (pyridin-2-yl) piperidin-4-yl.
[23" claim-type="Currently amended] The method according to any one of claims 1 to 18,
R ⁴ is-(C ₂ -C ₆ alkylene) -R ⁸ .
[24" claim-type="Currently amended] The method of claim 23,
R ⁴ is —CH ₂ CH ₂ R ⁸ .
[25" claim-type="Currently amended] The method according to any one of claims 1 to 18,
R ⁴ is-(C ₁ -C ₆ alkylene) -R ¹³ .
[26" claim-type="Currently amended] The method of claim 25,
R ⁴ is —CH ₂ R ¹³ or —CH ₂ CH ₂ R ¹³ .
[27" claim-type="Currently amended] The method according to any one of claims 1 to 18,
R ⁴ is C ₃ -C ₈ cycloalkyl.
[28" claim-type="Currently amended] The method of claim 27,
R ⁴ is cyclohexyl.
[29" claim-type="Currently amended] The method according to any one of claims 1 to 28,
R ⁵ is —CH ₂ OH or —CONH (C ₁ -C ₆ alkyl).
[30" claim-type="Currently amended] The method of claim 29,
R ⁵ is -CONHCH ₂ CH ₃ .
[31" claim-type="Currently amended] The method of claim 23 or 24,
Azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholine, wherein R ⁸ is (i) unsubstituted or substituted with C ₁ -C ₆ alkyl, respectively, on the ring carbon atom 4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, wherein the piperazin-1-yl and homopiperazin Or -1-yl is unsubstituted or substituted with C ₁ -C ₆ alkyl on a ring nitrogen atom which is not bonded to a C ₂ -C ₆ alkylene group; Or (ii) NR ¹¹ R ¹² .
[32" claim-type="Currently amended] The method of claim 31, wherein
R ⁸ is piperidin-1-yl or tetrahydroisoquinolin-1-yl, each substituted or unsubstituted with C ₁ -C ₆ alkyl on a ring carbon atom.
[33" claim-type="Currently amended] The method of claim 32,
R ⁸ is piperidin-1-yl, 4-isopropylpiperidin-1-yl or tetrahydroisoquinolin-1-yl.
[34" claim-type="Currently amended] The method of claim 31, wherein
R ⁸ is NR ¹¹ R ¹² and NR ¹¹ R ¹² is N (C ₁ -C ₆ alkyl) ₂ , N (C ₁ -C ₆ alkyl) (C ₃ -C ₈ cycloalkyl) or N (C ₁ -C ₆ alkyl) (benzyl).
[35" claim-type="Currently amended] The method of claim 34, wherein
NR ¹¹ R ¹² is N, N-diisopropylamino, N, N-di-n-butylamino, N-cyclopentyl-N-isopropylamino, N-cyclohexyl-N-isopropylamino or N-benzyl -N-isopropylamino.
[36" claim-type="Currently amended] The method of claim 31, wherein
R ¹¹ is H or C ₁ -C ₆ alkyl; R ¹² is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl.
[37" claim-type="Currently amended] The method of claim 36,
R ¹¹ is C ₁ -C ₆ alkyl; R ¹² is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl.
[38" claim-type="Currently amended] The method of claim 37,
R ¹¹ is isopropyl or n-butyl; R ¹² is isopropyl, n-butyl, cyclopentyl, cyclohexyl or benzyl.
[39" claim-type="Currently amended] The method of claim 25 or 26,
R ¹³ is phenyl unsubstituted or substituted with-(C ₁ -C ₃ alkylene) -NR ¹⁴ R ¹⁴ or -CO ₂ H; Or piperidin-2-yl, piperidin-3-yl or piperidin-4-yl, each substituted or unsubstituted with benzyl.
[40" claim-type="Currently amended] The method of claim 39,
R ¹³ is phenyl, 4- (N, N-diethylamino) methylphenyl, 4-carboxyphenyl or 1-benzylpiperidin-4-yl.
[41" claim-type="Currently amended] The method according to any one of claims 1 to 40,
Y is CO.
[42" claim-type="Currently amended] The method of claim 1,




Phosphorus compounds.
[43" claim-type="Currently amended] The method of claim 1,
6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2 -Furanyl} -N- {2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide Or a pharmaceutically acceptable salt or solvent compound thereof.
[44" claim-type="Currently amended] The method of claim 1,
4-[({[(2-{[(6-[(2,2-diphenylethyl) amino] -9-{(2R, 3R, 4S, 5S) -5-[(ethylamino) carbonyl] -3,4-dihydroxytetrahydro-2-furanyl} -9H-purin-2-yl) carbonyl] amino} ethyl) amino] carbonyl} amino) methyl] benzoic acid, or a pharmaceutical thereof Acceptable salt or solvent compounds.
[45" claim-type="Currently amended] 45. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 44, or a pharmaceutically acceptable salt or solvent compound thereof, together with a pharmaceutically acceptable excipient, diluent or carrier.
[46" claim-type="Currently amended] The method according to any one of claims 1 to 44 and 45,
A compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for use as a medicament.
[47" claim-type="Currently amended] The method according to any one of claims 1 to 44 and 45,
A compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for use as an A2a receptor agonist.
[48" claim-type="Currently amended] The method according to any one of claims 1 to 44 and 45,
A compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for use as an anti-inflammatory agent.
[49" claim-type="Currently amended] The method according to any one of claims 1 to 44 and 45,
A compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for use in treating a respiratory disease.
[50" claim-type="Currently amended] The method of claim 49,
The disease is selected from the group consisting of adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchiectasis, chronic sinusitis and rhinitis.
[51" claim-type="Currently amended] The method according to any one of claims 1 to 44 and 45,
Septic shock, male erectile dysfunction, male factor infertility, female factor infertility, hypertension, stroke, epilepsy, cerebral ischemia, peripheral vascular disease, post-ischemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis, allergic Dermatitis, eczema, ulcerative colitis, Crohn's disease, inflammatory bowel disease, Helicobacter pylori gastritis, non-helicobacter phyllori gastritis, gastrointestinal damage or psychotic disorders caused by nonsteroidal anti-inflammatory drugs A compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof, for treating or healing a wound.
[52" claim-type="Currently amended] Use of a compound of formula I according to any one of claims 1 to 44 and 45, or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of a medicament having A2a receptor agonist activity.
[53" claim-type="Currently amended] Use of a compound of formula I according to any one of claims 1 to 44 and 45, or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of an anti-inflammatory agent.
[54" claim-type="Currently amended] Use of a compound of formula (I) according to any one of claims 1 to 44 and 45, or a pharmaceutically acceptable salt, solvent compound or composition thereof, for the manufacture of a medicament for the treatment of respiratory diseases.
[55" claim-type="Currently amended] The method of claim 54, wherein
The disease is selected from the group consisting of adult respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchiectasis, chronic sinusitis and rhinitis.
[56" claim-type="Currently amended] Septic shock, male impotence, male factor infertility, female factor infertility, hypertension, stroke, epilepsy, cerebral ischemia, peripheral vascular disease, post-ischemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis, allergic Treating dermatitis, eczema, ulcerative colitis, Crohn's disease, inflammatory bowel disease, Helicobacter pylori gastritis, non-Helicobacter pylori gastritis, gastrointestinal damage or psychotic disorders caused by nonsteroidal anti-inflammatory drugs, or healing wounds Use of a compound of formula (I) according to any one of claims 1 to 44 and 45, or a pharmaceutically acceptable salt, solvent compound or composition thereof.
[57" claim-type="Currently amended] A2a receptor action, comprising treating a mammal with an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvent compound or composition thereof according to any one of claims 1 to 44 and 45. A method of treating a mammal comprising zero humans.
[58" claim-type="Currently amended] 46. An inflammatory disease comprising treating a mammal with an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvent compound or composition thereof according to any one of claims 1 to 44 and 45. A method of treating a mammal, including a human, for treatment.
[59" claim-type="Currently amended] A respiratory disease comprising treating a mammal with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof according to any one of claims 1 to 44 and 45. A method of treating a mammal, including a human, for treatment.
[60" claim-type="Currently amended] The method of claim 59,
The disease is selected from the group consisting of adult respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchiectasis, chronic sinusitis and rhinitis.
[61" claim-type="Currently amended] 46. A septic shock comprising treating a mammal with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvent compound or composition thereof according to any one of claims 1 to 44 and 45. , Male erectile dysfunction, male factor infertility, female factor infertility, hypertension, stroke, epilepsy, cerebral ischemia, peripheral vascular disease, post-ischemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis, allergic dermatitis, eczema To treat ulcerative colitis, Crohn's disease, inflammatory bowel disease, Helicobacter Philophyllitis, non-Helicobacter Philophyllitis, gastrointestinal damage or psychotic disorders caused by nonsteroidal anti-inflammatory drugs, or to heal wounds A method of treating a mammal comprising.
[62" claim-type="Currently amended] (a) reacting a compound of formula (II) with a compound of formula (III) wherein Y is CO and R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ¹⁵ and X are as defined in claim 1 To prepare a compound of I;
(b) aminocarbonylation of a compound of formula XVII with a compound of formula XVIII in the presence of carbon monoxide and a coupling catalyst;
(c) deprotecting the compound of formula XXI to remove the protecting group (s) together, alone or in any combination;
(d) reacting a compound of formula XXIVA with an amine of formula R ³ R ⁴ NH, wherein Y is CS and R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ¹⁵ and X are defined in claim 1 Preparing a compound of Formula I as shown;
(e) reacting a compound of formula XXVII with a compound of formula II as defined in (a) above so that Y is SO ₂ and R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ¹⁵ and X Preparing a compound of formula I as defined in claim 1;
(f) reacting a compound of formula XXIVB with an amine of formula R ³ R ⁴ NH where Y is C = N (CN) and R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ¹⁵ and X are To prepare a compound of formula I as defined in claim 1; or
(g) reacting a compound of formula XIV with an amine of formula XVIII;
A process for preparing a compound of formula I according to claim 1 which then comprises or does not convert the compound of formula I to a pharmaceutically acceptable salt thereof.
Formula II

Formula III
R ³ R ⁴ NCOZ ¹

Formula XVII

Formula XVIII
R ¹⁵ NH-X-NR ² -Y-NR ³ R ⁴
Formula XXI

Chemical Formula XXIVA

Formula XXIVB

Formula XXVII
R ³ R ⁴ NSO ₂ Z ⁷
In the above formulas,
R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ¹⁴ , R ¹⁵ , X and Y are as defined in claim 1;
Z ¹ , Z ³ , Z ⁵ , Z ⁶ , Z ⁷ , Z ⁸ and Z ⁹ are leaving groups;
R ^5A is CH ₂ OH, CH ₂ OR ²³ or CONR ¹⁴ R ¹⁴ ;
R ¹⁸ is an ester forming group;
R ²¹ and R ²² are each protecting groups or both are protecting groups;
R ²³ is a protecting group.
[63" claim-type="Currently amended] A compound of formula II:
Formula II

Where
R ¹ , R ² , R ⁵ , R ¹⁵ and X are as defined in claim 1.
[64" claim-type="Currently amended] Compounds of Formula XIV
Formula XIV

Where
R ¹ and R ¹⁴ are as defined in claim 1;
R ⁵ is CONR ¹⁴ R ¹⁴ ;
R ¹⁸ is an ester forming group.
[65" claim-type="Currently amended] A compound of formula
Formula XXI

Where
R ¹ , R ² , R ³ , R ⁴ , R ¹⁴ , R ¹⁵ , X and Y are as defined in claim 1;
R ^5A is CH ₂ OH, CH ₂ OR ²³ or CONR ¹⁴ R ¹⁴ ;
R ²¹ and R ²² are each protecting groups or both are protecting groups;
R ²³ is a protecting group.
[66" claim-type="Currently amended] Compounds of Formula (XXII)
Formula XXII

Where
R ¹ , R ² , R ³ , R ⁴ , R ¹⁵ , X and Y are as defined in claim 1.
[67" claim-type="Currently amended] Compounds of Formula (XXIV)

Where
R ¹ , R ² , R ³ , R ⁴ , R ¹⁵ , X and Y are as defined in claim 1;
R ²⁴ is a protecting group.
[68" claim-type="Currently amended] Compounds of Formula (XXV)

Where
R ¹ , R ² , R ¹⁵ and X are as defined in claim 1;
R ²⁴ is a protecting group.
[69" claim-type="Currently amended] A compound of formula XXXIII:

Where
R ¹ is as defined in claim 1;
R ¹⁸ is an ester forming group;
R ²¹ and R ²² are each a protecting group or both are protecting groups.
[70" claim-type="Currently amended] A compound of formula XXXIV:

Where
R ¹ and R ¹⁴ are as defined in claim 1;
R ¹⁸ is an ester forming group;
R ²¹ and R ²² are each a protecting group or both are protecting groups.
[71" claim-type="Currently amended] A compound of formula XXXV:

Where
R ¹ and R ¹⁴ are as defined in claim 1;
R ²¹ and R ²² are each a protecting group or both are protecting groups.
[72" claim-type="Currently amended] A compound of formula XXXVII:

Where
R ¹ is as defined in claim 1;
R ¹⁸ is an ester forming group.
[73" claim-type="Currently amended] A compound of formula XXXIX:

Where
R ¹ , R ² , R ³ , R ⁴ , R ¹⁵ , X and Y are as defined in claim 1;
R ²¹ and R ²² are each a protecting group or both are protecting groups.
[74" claim-type="Currently amended] A compound of formula XXXX:

R ¹ , R ² , R ³ , R ⁴ , R ¹⁵ , X and Y are as defined in claim 1;
R ²¹ and R ²² are each a protecting group or both are protecting groups.
[75" claim-type="Currently amended] Compounds of Formula XXIVA
Chemical Formula XXIVA

R ¹ , R ² , R ⁵ , R ¹⁵ and X are as defined in claim 1;
Z ⁵ and Z ⁶ are leaving groups.
[76" claim-type="Currently amended] Compounds of Formula (XXIVB)
Formula XXIVB

R ¹ , R ² , R ⁵ , R ¹⁵ and X are as defined in claim 1;
Z ⁸ and Z ⁹ are leaving groups.
[77" claim-type="Currently amended] Ethyl 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate;
Ethyl 9-{(2R, 3R, 4R, 5R) -3,4-bis (acetyloxy) -5-[(acetyloxy) methyl] tetrahydro-2-furanyl} -6-[(2,2 -Diphenylethyl) amino] -9H-purine-2-carboxylate;
Ethyl 9-[(2R, 3R, 4S, 5R) -3,4-dihydroxy-5- (hydroxymethyl) tetrahydro-2-furanyl] -6-[(2,2-diphenylethyl) Amino] -9H-purine-2-carboxylate;
Ethyl 9-[(3aR, 4R, 6R, 6aR) -6- (hydroxymethyl) -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-yl]- 6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylate;
(3aS, 4S, 6R, 6aR) -6- [6-[(2,2-diphenylethyl) amino] -2- (ethoxycarbonyl) -9H-purin-9-yl] -2,2- Dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-carboxylic acid;
Ethyl 9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4 -Yl} -6-[(2,2-diphenylethyl) amino] -9H-purin-2-carboxylate;
9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-yl } -6-[(2,2-diphenylethyl) amino] -9H-purine-2-carboxylic acid;
9-{(3aR, 4R, 6S, 6aS) -6-[(ethylamino) carbonyl] -2,2-dimethyltetrahydrofuro [3,4-d] [1,3] dioxol-4-yl } -6-[(2,2-diphenylethyl) amino] -N- {2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl} -9H-purine-2-carboxamide;
t-butyl 2-[({[1- (2-pyridinyl) -4-piperidinyl] amino} carbonyl) amino] ethyl carbamate;
N- (2-aminoethyl) -N '-[1- (2-pyridinyl) -4-piperidinyl] urea dihydrochloride; And
N- (2-aminoethyl) -N '-[1- (2-pyridinyl) -4-piperidinyl] urea.
[78" claim-type="Currently amended] A compound of formula (I), or a pharmaceutically acceptable salt or solvent compound thereof:
Formula I

Where
R ¹ is H, C ₁ -C ₆ alkyl or fluorenyl, wherein C ₁ -C ₆ alkyl is phenyl, optionally substituted with C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy, halo or cyano And it is unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of naphthyl;
R ² is H or C ₁ -C ₆ alkyl;
R ³ and R ⁴ together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each on a ring nitrogen or carbon atom Unsubstituted or substituted with -NR ⁶ R ⁷ on a ring carbon atom which is unsubstituted or substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl and which is not adjacent to the ring nitrogen atom; or
R ³ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl; R ⁴ is (a) azetidin-3-yl, pyrrolidin-3-yl, py, unsubstituted or substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl or het, respectively; Ferridin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, (b)-(C ₂ -C ₆ alkylene) -R ⁸ or (c)-(C ₁ -C ₆ alkylene) -R ¹³ ;
R ⁵ is CH ₂ OH or CONR ¹⁴ R ¹⁴ ;
R ⁶ and R ⁷ are independently of each other H or C ₁ -C ₆ alkyl; Or together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl or piperidinyl, each substituted or unsubstituted with C ₁ -C ₆ alkyl;
R ⁸ is (i) C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₁ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring carbon atom Ring nitrogen atoms, each substituted or unsubstituted with (C ₁ -C ₆ ) -alkyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ⁹ or C ₂ -C ₅ alkanoyl and a fluoro-on ring carbon atoms that are not adjacent - (C ₁ -C ₆₎ - alkoxy, halo, -OR ^{9, _{cyano, -S (O) m R 10}} , -NR 9 R 9, -SO 2 NR 9 Azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4, unsubstituted or substituted with R ⁹ , -NR ⁹ COR ¹⁰ or -NR ⁹ SO ₂ R ¹⁰ . -Yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, wherein said piperazin-1-yl and homopiperazin- 1-yl is C ₁ -C ₆ alkyl, phenyl, C ₁ -C ₆ alkoxy- (C ₂ -C ₆ ) -alkyl, R ⁹ R ⁹ N- on a ring nitrogen atom which is not bound to a C ₂ -C ₆ alkylene group (C ₂ -C ₆ ) -alkyl, flu Oro - (C ₁ -C ₆₎ - alkyl, C ₂ -C ₅ alkanoyl, -COOR ^10, C ₃ -C _{8 ^{cycloalkyl, -SO 2 R 10, -SO 2}} NR 9 R 9 or -CONR ⁹ R Substituted or unsubstituted with ⁹ ; Or (ii) NR ¹¹ R ¹² ;
R ⁹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
R ¹⁰ is C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or phenyl;
R ¹¹ is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl or benzyl;
R ¹² is H, C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, phenyl, benzyl, fluoro- (C ₁ -C ₆ ) -alkyl, -CONR ⁹ R ⁹ , -COOR ¹⁰ , C _2- C ₅ alkanoyl or —SO ₂ NR ⁹ R ⁹ ;
R ¹³ is phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, optionally substituted with C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy, halo or cyano;
R ¹⁴ is H, or C ₁ -C ₆ alkyl optionally substituted with cyclopropyl;
R ¹⁵ is H or C ₁ -C ₆ alkyl;
m is 0, 1 or 2;
X is unbranched C ₂ -C ₃ alkylene optionally substituted with C ₁ -C ₆ alkyl or C ₃ -C ₈ cycloalkyl;
Y is CO, CS, SO ₂ or C = N (CN);
"Het" as used in the definition of R ⁴ is substituted with C ₁ -C ₆ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₆ alkoxy, C ₃ -C ₈ cycloalkoxy, hydroxy, oxo or halo or Unsubstituted 1 to 4 ring nitrogen heteroatoms, or C-bonded 4 to 6 membered ring heterocycles having 1 or 2 nitrogen ring heteroatoms and 1 oxygen or 1 sulfur ring heteroatom.

类似技术:

---

公开号 | 公开日 | 专利标题

---

KR102108864B1|2020-05-12|Methods for the preparation of diasteromerically pure phosphoramidate prodrugs

---

AU2010257449B2|2012-03-22|New crystalline and amorphous form of a triazolo|pyrimidine compound

---

Harnden et al.1987|Synthesis and antiviral activity of 9-[4-hydroxy-3-| but-1-yl] purines

---

US5607922A|1997-03-04|1,5-anhydrohexitol nucleoside analogues

---

JP2675749B2|1997-11-12|Desazapurine-nucleoside-derivative

---

US5364862A|1994-11-15|Compounds having antihypertensive and anti-ischemic properties

---

ES2222619T3|2005-02-01|Adenosine receiver agonists a1.

---

US4843066A|1989-06-27|Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient

---

EP1379520B1|2006-04-26|N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

---

KR101081226B1|2011-11-07|Inhibitors of nucleoside phosphorylases and nucleosidases

---

RU2157215C2|2000-10-10|Method of treatment of patients with infections induced by hepatitis b virus

---

RU2298557C2|2007-05-10|Agonists of adenosine a3-receptors

---

US8227431B2|2012-07-24|Nucleoside derivatives

---

JP5213194B2|2013-06-19|4'-C-substituted-2-haloadenosine derivatives

---

ES2276515T3|2007-06-16|2'-fluoronucleosids.

---

US7414036B2|2008-08-19|Compounds useful as A3 adenosine receptor agonists

---

ES2201552T3|2004-03-16|Adenosine receiver a1 agonists.

---

JP4265969B2|2009-05-20|4'-substituted nucleosides

---

DK170894B1|1996-03-04|Adenosine derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the compounds

---

RU2067097C1|1996-09-27|Process for preparing didesoxydidehydrocarbocyclic nucleosides

---

US5559101A|1996-09-24|L-ribofuranosyl nucleosides

---

US6455507B1|2002-09-24|Benzimidazole derivatives

---

US6214807B1|2001-04-10|C-pyrazole 2A A receptor agonists

---

KR100789162B1|2007-12-28|Synthesis of 2'-deoxy-L-nucleosides

---

JP4639032B2|2011-02-23|3'-prodrug of 2'-deoxy-β-L-nucleoside

同族专利:

---

公开号 | 公开日

---

CN1249074C|2006-04-05|

---

TWI227240B|2005-02-01|

---

JP2008150383A|2008-07-03|

---

AU2001260537B2|2006-05-25|

---

HU0301330A2|2003-08-28|

---

PL360435A1|2004-09-06|

---

NZ522184A|2004-05-28|

---

CA2414018A1|2001-12-13|

---

CU23240B7|2007-10-17|

---

ES2324816T3|2009-08-17|

---

EA004983B1|2004-10-28|

---

AT431356T|2009-05-15|

---

NO324426B1|2007-10-08|

---

EP1292604B1|2009-05-13|

---

OA12279A|2003-01-01|

---

HRP20020960A2|2005-02-28|

---

EA200201179A1|2003-04-24|

---

NO20025821D0|2002-12-04|

---

AU6053701A|2001-12-17|

---

WO2001094368A1|2001-12-13|

---

PA8518801A1|2002-09-17|

---

MA26910A1|2004-12-20|

---

BG107216A|2003-05-30|

---

HK1089447A1|2008-08-22|

---

GC0000287A|2006-11-01|

---

EP1292604A1|2003-03-19|

---

HK1054042A1|2006-09-01|

---

MXPA02012033A|2003-04-25|

---

BR0111263A|2003-06-17|

---

DE60138702D1|2009-06-25|

---

JP2003535871A|2003-12-02|

---

IS6599A|2002-10-29|

---

AR030289A1|2003-08-20|

---

CZ20023875A3|2004-02-18|

---

SK16752002A3|2004-05-04|

---

KR100484704B1|2005-04-22|

---

DK1292604T3|2009-06-15|

---

EE200200678A|2004-06-15|

---

NO20025821L|2003-02-04|

---

IL152783D0|2003-06-24|

---

IL184144A|2008-11-26|

---

IL184144D0|2007-10-31|

---

HU0301330A3|2005-02-28|

---

DZ3439A1|2001-12-13|

---

JP4129176B2|2008-08-06|

---

CA2414018C|2007-10-16|

---

CN1434830A|2003-08-06|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2000-06-06|Priority to GB0014048.3

---

2000-06-06|Priority to GB0014048A

---

2000-07-25|Priority to GB0018246A

---

2000-07-25|Priority to GB0018246.9

---

2000-10-11|Priority to GB0024920A

---

2000-10-11|Priority to GB0024920.1

---

2001-06-05|Application filed by 화이자 인코포레이티드

---

2001-06-05|Priority to PCT/IB2001/000973

---

2003-04-26|Publication of KR20030032962A

---

2005-04-22|Application granted

---

2005-04-22|Publication of KR100484704B1

优先权:

---

申请号 | 申请日 | 专利标题

---

GB0014048.3|2000-06-06|

---

GB0014048A|GB0014048D0|2000-06-06|2000-06-06|Purine derivatives|

---

GB0018246A|GB0018246D0|2000-06-06|2000-07-25|Purine derivatives|

---

GB0018246.9|2000-07-25|

---

GB0024920A|GB0024920D0|2000-06-06|2000-10-11|Purine derivatives|

---

GB0024920.1|2000-10-11|

---

PCT/IB2001/000973|WO2001094368A1|2000-06-06|2001-06-05|2-aminocarbonyl-9h-purine derivatives|